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Zusammenfassung 
 
Magnetische Nanopartikel (MNP) wurden in den letzten Jahren stetig weiter entwickelt und 
leisten bereits heute einen wichtigen Beitrag auf dem Gebiet der medizinischen Diagnose und 
Behandlung. Einsatzbereiche beinhalten sowohl “drug delivery” Systeme als auch 
Kontrastmittel, welche z.B. in der Magnetresonanztomographie (MRT) zum Einsatz kommen. 
Zellen des angeborenen Immunsystems stellen wichtige Mediatoren in sowohl der 
Identifizierung als auch der Beseitigung eingehender Infektionen dar und tragen merklich zur 
Einleitung immunologischer Wechselwege bei. 
Blut-bildende Stammzellen und sich daraus ableitende Vorläuferzellen stellen wegen ihrem 
hohen Grad an Plastizität effektive Ziele von zell-basierenden Therapien dar. Darüber hinaus 
besitzen sie die Fähigkeit, den gesamten Zellpool des hematopoietischen Systems zu 
rekonstituieren. Auf der anderen Seite stellen terminal differenzierte Immunzellen wie z.B. 
Makrophagen und dendritische Zellen (DC) aufgrund ihrer immunologischen Merkmale 
optimale Markierungsagenzien dar. Makrophagen leisten einen besonderen Beitrag zur 
Identifizierung und Beseitigung eingehender Infektionen durch Unterstützung einer 
geeigneten Immunantwort. Professionelle Antigen-präsentierende DC spielen eine 
Schlüsselrolle bei der Einleitung einer primären adaptiven Immunantwort, welche in einer 
Antigen-spezifischen Aktivierung von B- und T-Lymphozyten in sekundären Lymphorganen 
resultiert. Aufgrund dieser und anderer Tatsachen stellen sie ein attraktives Ziel dar, mit 
dessen Hilfe zelluläre Impfstoffe und Kontrastmittel für die molekulare Bildgebung 
entwickelt werden können. Deshalb werden sie derzeit in vielen klinischen Studien eingesetzt. 
Dennoch sind die (i) Interaktionen von magnetischen Nanopartikeln mit einer gegebenen Ziel-
Zellpopulation, die (ii) Induktion eines gewünschten Zell-Phänotyps mittels gezielten 
Markierungsstrategien, sowohl die (ii) daraus resultierenden MNP Bildgebungseigenschaften 
in der MRT äußerst wichtig für den Verlauf dieser Zell-basierenden Therapieansätze. Auch 
wenn sie bereits zu einem gewissen Grad in klinischen Studien zur Anwendung kommen, 
mangelt es derzeit noch an systematischen Forschungsansätzen. Das Wissen über die 
grundlegenden Mechanismen der zellulären MNP Aufnahme, phenotypischen Veränderungen 
markierter Zellen und daraus resultierenden Bildgebungseigenschaften befindet sich noch im 
Anfangsstadium. 
Aus diesem Grund wurden in dieser Studie synthetische MNP auf Basis von Eisenoxid 
entwickelt und hergestellt, welche spezifische biologisch inaktive oder aktive Oberflächen 
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besitzen. Diese beinhalten unter anderem Bio-Makromoleküle, poly-Elektrolyte, sowie 
Strukturen bakteriellen und viralen Ursprungs. Diese experimentelle Plattform ermöglichte es 
uns, sowohl quantitative als auch qualitative Aufnahme der MNP, phänotypische 
Zustandsänderungen der markierten Zellen, als auch daraus resultierende 
Bildgebungseigenschaften in Immunzellen zu studieren. Durch die Nutzung von bakteriellen 
MNPs, sogenannten Magnetosomen, war es uns möglich, Mechanismen und Wege der 
Internalisierung im Kontext von Toll-like Rezeptor (TLR) sowie Signalproteinen zu 
untersuchen. Darüber hinaus erörterten wir die Rolle des evolutionär konservierten 
Inflammasom-Signalweges, um immunologische Konsequenzen der verschiedenen MNP 
Rezepturen mittels Zellen des angeborenen Immunsystems zu erforschen. 
Zusammenfassend liefert diese Studie Erkenntnisse über intrazelluläres Nanopartikel-
Shuttling sowie Agglomeration, welche die MR Bildgebung signifikant beeinflussen. TLR 
und Signalprotein-Studien erbrachten Hinweise über alternative Aufnahmemechanismen 
sowie Art und Ausmaß der kompromitierten Immunantwort im Falle eines fehlenden Proteins. 
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Abstract  
 
Engineered magnetic nanoparticles (MNPs) are currently emerging as promising tools in 
numerous applications for medical theragnostics including the development of drug delivery 
systems and contrast agents for magnetic resonance imaging (MRI). In vitro labeling of target 
cell populations with MNPs before therapeutic implantation shows great promise in 
monitoring successful cell engraftment, differentiation and migratory behavior using MRI. 
Depending on the desired therapeutic treatment outcome, these biological processes remain 
critical for the success of cell-based therapies. 
Hematopoietic stem and their derived precursor cells are particularly suited for cell-based 
therapies due to their plasticity and ability to reconstitute the entire cell pool of the 
hematopoietic system in both steady-state and disease. Terminally differentiated immune cells 
such as macrophages and dendritic cells (DCs) represent optimal labeling agents due to their 
potential to initiate immune responses within the host. Macrophages are promising agents of 
the innate immunity and are crucial in identifying and clearing initial harmful threats through 
shaping subsequent immunological consequences. Professional antigen-presenting immune 
cells, such as DCs, play a key role in the induction of adaptive immune responses that result 
in the antigen-specific activation of B- and T-lymphocytes in secondary lymphoid organs. 
Taken together, this makes them a particularly attractive target for the development of cellular 
vaccines and contrast agents for MRI. Therefore, they are increasingly applied in clinical 
trials of today. 
However, (i) the interaction of MNP formulations with a given target cell population, (ii) the 
induction of a desired immunological phenotype through targeted cell labeling strategies, and 
(iii) resulting MNP imaging properties using MRI remain largely unknown. Even though 
already in clinical practice, a systematic investigation of MNP uptake, phenotypic alteration 
of recipient cells and resulting MR imaging properties are still lacking and underlying 
mechanisms are poorly understood. 
In this study, we engineered iron oxide based MNPs displaying distinct biologically inert or 
active surface coatings including bio-macromolecules, polyelectrolytes as well as shell 
structures of bacterial and viral origin. Given this experimental platform, we investigated 
quantitative and qualitative uptake of MNPs into target cells, phenotypic alterations of labeled 
cells and resulting imaging characteristics. Through employing bacterial magnetosome MNPs 
that possess pathogen-associated molecular patterns as an integral component on their surface 
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structures, mechanisms and routes of internalization were investigated in the context of toll-
like receptors and signaling adaptor knockout mice. In addition, activation of the 
evolutionarily conserved inflammasome pathway was studied to investigate immunological 
consequences of MNP formulations in cells of the innate immune system. 
Taken together, this study provides insights into MNP interactions with cells of the 
hematopoietic system. We provide evidence that shuttling and clustering characteristics inside 
target cells substantially shape MR imaging properties. Both uptake magnitude and MNP 
packaging properties within cells conferred MR contrast that was influenced by MNP surface 
chemistry. We believe these findings will aid in the future development of MNPs for cell 
labeling strategies designed for a pre-determined imaging purpose. 
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1 Introduction 
 
1.1 Molecular Imaging in Modern Medicine 
Molecular imaging emerged in the early twenty-first century as a discipline at the intersection 
of molecular biology and in vivo imaging. Although it lacks a universal definition, molecular 
imaging is often considered the non-invasive, quantitative, and repetitive imaging of targeted 
macromolecules and biological processes in living organisms
[1]
. Today, the most common 
molecular imaging techniques used in both research settings as well as clinical practice are 
positron emission tomography (PET), optical imaging, computed tomography (CT), 
ultrasound and magnetic resonance imaging (MRI)
[2,3]
. 
The multiple and numerous potentialities of these imaging modalities are applicable to the 
diagnosis of diseases (e.g. cancer) through altered molecular profiles and/or cell behavior 
prior to visual anatomic alterations
[4]
. Therefore, the employment of molecular imaging could 
potentially allow for (i) early detection of disease, (ii) more accurate prognoses and 
personalized treatments, (iii) the ability to monitor the effectiveness of therapeutic treatment 
regimes, and (iv) improvements in our understanding of how cells behave and interact within 
their micro-environment in living subjects
[5]
. 
Furthermore, PET and MRI have recently gained much interest in the field of medical 
research due to the fact that they allow the study of molecular mechanisms non-invasively
[4]
. 
This permits researchers to gain valuable knowledge of functional processes in health and 
their alterations in disease states that in turn lead to the development of more sophisticated 
imaging agents. 
 
1.1.1 Bridging Biology, Chemistry and Molecular Imaging 
Cells, either being normal or aberrant, cannot easily be distinguished from each other by in 
vivo imaging. In order to enhance imaging contrast of biological target structures from 
surrounding tissues, chemically synthesized contrast agents are being employed
[6]
. These 
molecular imaging vectors aid the visualization of biological processes and range from 
fluorescent probes (optical imaging) to α-radiation emitters (PET, single-photon emission 
computed tomography (SPECT)) up to nano-scale contrast agents (MRI)
[3,7]
. In therapeutic 
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and diagnostic applications of today, these vectors are obligated to fulfill distinct criteria to 
permit imaging of specific molecules in vivo, in particular: (i) the availability of high affinity 
probes with reasonable pharmacodynamics, (ii) the ability of these probes to overcome 
biologic delivery barriers (vascular, interstitial, cell membrane), (iii) the use of amplification 
strategies (chemical or biological), and (iv) the availability of sensitive, fast, high resolution 
imaging techniques
[8]
. 
 
1.1.2 Labeling Agents in Molecular Imaging 
Potential labeling agents for applicable molecular imaging modalities possess functionalities 
related to their respective imaging goal and imaging modality at hand. In brief, three 
categories of labeling agents are being employed today: genetic reporters, injectable contrast 
agents and exogenous cell trackers
[2]
. These vectors allow targeting of a specific tissue, cell or 
even molecule, and thus, facilitate direct interaction and/or binding with ligand moieties that 
ultimately enhances molecular imaging characteristics. 
Although still limited to experimental mouse models, genetic reporters are cloned into the 
promoter or enhancer region of a gene of interest to be expressed concomitantly
[9]
. The type 
of imaging protein expressed is related to both (i) the research question at hand and (ii) the 
imaging modality to be employed, e.g. fluorescent markers in optical imaging
[10]
. 
Injectable contrast agents on the other hand are more widely used even in clinical settings
[7]
. 
However, due to stringent design criteria to minimize background signals and yield high local 
concentrations at the intended sites, a lot of research is devoted to understanding the 
molecular mechanisms involved in vector accumulation and clearance
[10,11,12]
. This process 
will aid in the future optimization of systemically administered contrast agents to maximize 
their target-to-background ratios, and thus, improve their imaging potential
[2]
. 
Exogenous cell trackers are being increasingly employed using adoptive cell transfer therapies, 
including immunotherapeutic strategies
[13]
. In order to monitor therapeutic progression, 
exogenous cell trackers allow a specific ex vivo targeting of distinct cell populations prior to 
re-administration. To non-invasively track fate and localization of implanted target cells in 
vivo after vector targeting, molecular imaging modalities such as MRI have been the method 
of choice
[14,15,16]
. 
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1.2 Magnetic Resonance Imaging (MRI) 
MRI has been widely used in both diagnostics and treatment regimes. Due to its capability to 
non-invasively monitor target tissues within their detailed anatomical context, MRI has 
advanced to an indispensable imaging tool in molecular medicine
[17,18]
. 
 
1.2.1 Physical Principle of MRI 
Magnetic resonance tomography is based on the absorption and emission of energy in the 
radio frequency range of the electromagnetic spectrum and was first characterized in 1946
[19]
. 
Produced images derive from spatial variations in the phase and frequency of the radio energy 
being absorbed and emitted by the imaged object
[20]
. Biological systems such as rodents and 
humans mostly consist of water molecules composed of hydrogen and oxygen atoms. Nuclei 
of hydrogen protons possess a quantum mechanical property - the nuclear spin angular 
momentum (I) - that can be quantified using the Plank constant h as follows: 
 
| |  
 
  
√ (   ) 
 
Hydrogen possesses a nuclear spin quantum number of ½. Placed in an external magnetic 
field (B0), the hydrogen spin will precess about B0 with the Larmor frequency (ω) in a discrete 
direction. The spin of ½ enables two possible alignments corresponding to the energy level of 
the nucleus. The distribution of the spins between the two possible energy states follows a 
Boltzmann distribution, which is dependent on the temperature T and the energy difference 
ΔE between the allowed states. The Boltzmann constant is represented by k. 
 
     
     
    ( 
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For hydrogen, the two energy states are N+1/2 spin ‘up’ (low energy) and N-1/2 spin ‘down’ 
state (high energy). The Boltzmann distribution shows that at 37°C (average body 
temperature) slightly more spins occupy the lower energy state, thus generating the net 
magnetization vector M. These excess spins are used to generate the MR signal. The energy 
difference between the high and low energy states is proportional to the strength of the 
externally applied magnetic field B0. Thus, the greater the strength of the external field, the 
greater the energy difference between the two spin states. 
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A second radiofrequency pulse, which is perpendicular to B0, can now be applied to generate 
field B1 (Figure 1.1). This field causes spins to flip off the z-axis and turn the net 
magnetization towards the transverse plane (x and y axis). The precessing about the z-axis in 
a xy-plane generates a detectable field. After switching off the previously applied pulse, the 
generated B1 ceases to exist and the nuclear spins return to their ground state. This process is 
called relaxation. The time required to return to the ground state is termed relaxation time. 
Relaxation time data of measured samples are used to produce the MR image. 
Relaxation can be subdivided into two physical phenomena occurring simultaneously: The 
recovery toward equilibrium alignment and the transverse decay
[20]
. The return of the M 
alignment around the z-axis to equilibrium by a time constant is termed the spin-lattice 
relaxation T1. Duration of the return from transverse decay is described as spin-spin 
relaxation T2. T1 and T2 are properties of the water milieu due to the presence of 
physicochemical microenvironments, the biological composition such as water mobility, the 
presence of microstructures, macromolecules and membranes
[21,22]
. These parameters provide 
MRI its power to distinguish between different tissues. 
 
1.2.2 MRI Contrast Agents  
Since hydrogen protons are naturally present in biological specimens, MR imaging can be 
performed without employing contrast agents. However, these agents are often being used to 
enhance imaging of target structures within their anatomical background to improve disease 
diagnosis and therapeutic monitoring
[23]
. MRI contrast agents are a class of pharmaceuticals 
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that enhance the image contrast between tissues in which the agent accumulates and their 
anatomical surroundings. This provides superior differentiation of normal from aberrant 
tissues and delivers information about the status of e.g. organ function or blood flow
[22]
. 
Generally speaking, contrast agents can be divided into two categories, namely paramagnetic 
and superparamagnetic compounds
[6]
. Most commonly, Gadolinium (III) (Gd) chelates are 
employed as paramagnetic contrast agents that predominantly reduce T1 relaxation times 
(spin-lattice relaxation). They are referred to as positive MRI contrast agents because they 
enhance signal intensity compared to their unlabeled surroundings. Gd represents a lanthanoid 
that belongs to the group of rare earth metals that is frequently employed in molecular 
imaging regimes. However, as free solubilized aqueous ion, Gd possesses high cellular 
toxicity, potentially leading to e.g. anaphylactic shock, renal dysfunction and possibly, 
lethality. In order to harness its potential as MRI contrast agent, it is frequently chelated to e.g. 
di-ethylene-tri-amine-pent-acetate (DTPA) or similar compounds. The resulting stable 
contrast agents such as Magnevist® (DTPA stabilized) are frequently used in MRI scans to 
enhance imaging of e.g. vasculature
[24]
. 
Superparamagnetic contrast agents on the basis of iron oxide are comprised of metallic core 
structures and surrounding layer(s) of coating to confer particle biocompatibility, 
monodispersity and stability
[25]
. Cores are typically composed of magnetite (Fe3O4) and/or 
maghemite (γFe2O3), with maghemite resembling the oxidized form of magnetite. Iron oxide 
based contrast agents are further sub-divided according to their overall size, namely: oral-
SPIO (small particles iron oxide) (300nm - 3.5µm), SPIO (60 - 150nm), ultra-small SPIO 
(USPIO) (10 - 40nm), and monocrystalline iron oxide nanoparticles (MION) (10 - 30nm). In 
general, SPIO exceeding a hydrodynamic size of 50nm are comprised of multiple iron oxide 
crystals. Their mode of action underlies their ability to elicit substantial disturbances in the 
local magnetic field. This is achieved through large magnetic moments that lead to a rapid 
dephasing of adjacent protons, thus generating a detectable change in MR signal. Iron oxide 
MNPs represent ferromagnetic materials that reduce T1, T2 and T2* relaxation times. 
However, in contrast to T1 contrast agents, they lead to an enhanced decrease of the MR 
signal, and thus, are being referred to as negative contrast agents
[26]
. 
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1.2.3 Contrast Agent Development for Cell-Based Therapeutic Applications 
Even though MRI represents a powerful imaging tool, its molecular detection limit is not 
superior when compared to other imaging modalities such as PET or optical techniques. To 
overcome its inherent lack of sensitivity, constant optimization of contrast agents is crucial for 
the improvement of disease diagnosis and treatment regimes in the future. A lot of 
interdisciplinary research is being devoted to develop contrast agents that are able to target 
specific cell types via distinct uptake routes as well as enhancing physico-chemical imaging 
characteristics, thereby optimizing imaging potential
[27,28]
. 
In a given clinical or research setting, both size as well as the surface decoration of contrast 
agents add up to yield (i) systemic half-lives and clearance, (ii) preferred sites of vector 
accumulation, and (iii) specific cell/tissue targeting. Shell structures of contrast agents are 
designed to facilitate targeted uptake or evade clearance mechanisms, thus extending their 
circulation time or being accumulated at sites of interest. This in turn leads to a significant 
improvement of MR imaging contrast. 
In diseases of the modern age, such as cancer, cardiovascular, autoimmune diseases and 
allergies, cells of the immune system and their precursors have been utilized as biological 
targets for intervention/therapeutic strategies in combination with exogenous cell 
trackers
[13,29,30,31]
. This includes CD34
+
 stem cells, their immediate progenitors and terminally 
differentiated immune cells. Due to their plasticity and inherent biological functions, they 
represent a promising tool for research as well as diagnostic and therapeutic applications
[32,33]
. 
Recent development in the field of nanotechnology allows the labeling and monitoring of 
these therapeutically administered cellular vectors in combination with molecular imaging 
modalities such as MRI. It has been widely established that these techniques in combination 
with administered contrast agents are crucial for the success to such cell-based therapies
[14,34]
. 
 
1.3 Hematopoietic Stem Cells and their Progeny 
Stem cells can be defined as cells that retain both self-renewing capabilities as well as the 
potential to give rise to clonal progeny with the ability to differentiate
[35,36]
. All adult blood 
cells, including red blood cells, platelets, and terminally differentiated immune cells, derive 
from hematopoietic stem cells (HSCs). These multipotent HSCs reside in specialized 
microenvironments termed “niches” that nourish and sustain their existence within the bone 
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marrow
[37]
. By undergoing both symmetric and asymmetric cell division events, HSCs either 
maintain a constant pool of identical progeny on the one hand, while developing into 
downstream progenitors and eventually into terminally differentiated “effector” cell types on 
the other
[38]
. Effector cells arise as a result of successive restriction and commitment events 
that are tightly regulated by both the action of transcription factors and the local cellular 
micro-environment provided by the stem cell niche
[39,40]
. 
Successive differentiation events can be envisioned as a branching family tree that diverges 
with progressing levels of cellular commitment steps (Figure 1.2). Within this hierarchy, 
HSCs represent the upper-most entity that is capable of giving rise to immediate precursor 
cells of the myeloid (MP) and lymphoid (LP) lineage of blood cells
[41]
. In turn, these partially 
committed precursors further differentiate into MDPs (monocyte, macrophage and dendritic 
cell (DC) precursors) and CDPs (common DC precursors), potentially capable of giving rise 
to the different subsets of monocytes, macrophages, and DCs. After the initial differentiation 
steps, terminally differentiated immature immune cells as well as late stage precursor cells 
leave the bone marrow to home into their final destination. As illustrated in Figure 1.2, 
crosstalk between the two separated branches of commitment ultimately leads to the 
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generation of the entire cellular blood pool, allowing the immune system to replenish cells in 
steady-state and react to arising inflammatory conditions
[42]
. 
 
1.4 Immune System 
Throughout evolution, biological systems had to develop a sophisticated means of coping 
with the constant threat of invading pathogens such as e.g. bacteria and viruses. Depending on 
the nature, number, and entry point of the invaders, immune systems need to be capable of 
initiating an appropriate enzymatic, cellular, and/or humoral counter-measure to fight and 
eliminate any potential exogenous environmental hazards or endogenous cellular 
abberations
[43,44]
. To accomplish this difficult task, most biological systems have developed 
two distinct divisions within their immune system, the so-called innate and adaptive 
immunity
[45,46,47]
. 
Innate immune systems provide immediate defense mechanisms against numerous infectious 
agents and are present in all living organisms
[48]
. In jawed vertebrates, evolution has led to the 
formation of the so-called acquired or adaptive immunity based on specialized cell pools that 
allow antigen-specific recognition and long-term protective immunity against encountered 
antigens
[49]
. 
As illustrated in Figure 1.3, both immune branches consist of distinct cell types responsible 
for the recognition, engagement and subsequent clearing of pathogens. Non-cellular protein 
components such as the complement system or immunoglobulins exist in both arms of 
immunity and have evolved to aid in cellular counteractive measures that restore health. 
Innate and adaptive immune countermeasures co-exist and mechanisms are interconnected to 
ensure proper functionality, even though the molecular diversity of pathogens is confronted in 
fundamentally different ways
[43]
. 
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1.4.1 Innate Immunity 
Agents of the innate immunity are represented by physical barriers such as the skin and 
mucosal surfaces lining potential entry points as found in the respiratory and gastrointestinal 
tract. Desquamation of the skin, antimicrobial enzymes present in saliva and tears, and the 
acidic pH milieu of the stomach represent the non-cellular components of the innate immune 
system
[49]
. Another hallmark of the innate immune defenses is the complement system, which 
represents yet another versatile defense machinery of non-cellular countermeasures
[50]
. It 
provides the capability to (i) opsonize antigens and (ii) release soluble chemotactic molecules 
attracting various cell types of both innate and adaptive immunity and (iii) lyse invading cells 
through actions of the “membrane attack complex”[51]. Dedicated scavenger cells clear sights 
of primary invasions as well as eliminating cell debris and dying cells, thereby also 
contributing to physiological homeostasis
[41,52]
. 
Recognition of pathogens is achieved through germline encoded pattern recognition receptors 
(PRRs) present on all cell types of the innate immune system. Throughout evolution, these 
trans-membrane signaling receptors have co-evolved with pathogen-associated molecular 
patterns (PAMPs) present on e.g. bacteria to recognize a broad spectrum of evolutionary 
10 | I n t r o d u c t i o n  
conserved and invariant antigens
[46]
. However, in contrast to the antigen receptor repertoire of 
the adaptive immune system, innate PRRs are only capable of limited antigen recognition. 
Innate defense mechanisms are always turned on, and, unlike acquired immunity, do not need 
a series of events and time leading to their full capacity
[53]
. Therefore, it is being referred to as 
rapid response system that is capable of engaging potentially harmful invading pathogens 
without a lag or adaptation phase based on the actions of both cellular factors as well as 
protein complexes such as e.g. the complement cascade
[54]
. 
The immune cells of the innate defense are mainly comprised of professional phagocytes, 
among them monocytes, macrophages, and DCs (Fig. 1.3)
[55]
. Neutrophils, a specialized 
short-lived population of granulocytes, also exert a very high phagocytic potential
[56]
. In 
combination with basophils and eosinophils, they aid in both the (i) destruction of invading 
pathogens and (ii) immune cell recruitment to sites of inflammation through the action of e.g. 
histamine and prostaglandins
[57]
. Furthermore, both granulocytes and natural killer (NK) cells 
are potent direct killers of certain pathogens once opsonized by antibodies, complement 
proteins or after PAMP recognition
[58,59]
. In addition, NK cells are crucially involved in 
defense strategies against viral infections
[60]. Through a continuous sensing of “self” protein 
motifs on somatic cell membranes in the context of Major Histocompatibility Complex class I 
(MHC I) molecules, NK cells are capable of detecting and destroying invaded cells by 
recognizing a concept termed “missing or altered self”[61]. Mast cells represent tissue-resident 
cells involved in inflammation and recruitment of additional immune cells to sites of antigenic 
contact. They highly express FcεRI receptors capable of irreversibly binding Fc regions of 
IgE antibodies produced by plasma cells. Upon antigen contact and antibody cross-linking 
they release the content of their intracellular granula into the interstitium
[62]
. 
As depicted in Figure 1.4, monocytes give rise to a variety of tissue-resident cell types of the 
immune system
[63]
. They are known to originate directly from the bone marrow as a 
consequence of asymmetric HSC divisions that give rise to a Ly6C
+
 common myeloid 
progenitor which is released into the peripheral blood
[64]
. After circulating for up to several 
days they enter the tissues in order to replenish e.g. tissue macrophage and DC populations in 
steady-state. Danger signals elicit increased recruitment of monocytes to sites of inflammation 
in a CCR2/CCR7 dependent manner prior to differentiation into macrophages and DCs that 
contribute to host defense, tissue remodeling and subsequent repair
[65]
. 
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Upon encountering various chemotactic signals that strongly depend on the composition of 
inflammatory mediators secreted within the local micro-environment, blood-borne monocytes 
differentiate into macrophages and extravasate into sites of potential danger. In steady-state, 
they populate virtually all tissues, where they reside and sense potentially harmful antigens 
within their immediate environment
[63]
. These tissue-specific macrophages constitute the 
reticuloendothelial system (RES), which is responsible for the physiological clearance of 
particles, apoptotic cells and pathogens. Macrophages display remarkable plasticity allowing 
them to efficiently respond to environmental signals
[66]
. In order to do this, they are equipped 
with PRR surface receptors that recognize evolutionary conserved protein motives on 
pathogens including toll-like receptors (TLRs) and interleukin-1 receptor
[67]
. The most 
important phenotypes of macrophages resemble M1 and M2 activation states
[68,69]
. M1 
macrophages are being activated via IFNγ and TLR stimulation, resulting in elevated 
expression of MHC II, IL-12, and TNFα. These in turn lead to the generation of reactive 
oxygen species (ROS) and nitric oxide (NO) that are involved in the destruction of pathogens 
or aberrant cells
[70]
. On the contrary, the presence of IL-4 and IL-13 results in the 
differentiation of macrophages into M2 that is involved in Th2 immune responses including 
humoral immunity and wound healing
[71]
. 
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Dendritic cells on the other hand represent the bridge between innate and adaptive immunity 
because they serve as sentinels in peripheral tissues as well as being professional antigen-
presenting cells that stimulate naïve T- and B cells in secondary lymphoid organs
[72]
. They 
possess a high phagocytic and macropinocytic activity when in an immature phenotype in 
peripheral tissues
[73]
. DCs are also critically involved in both central as well as peripheral 
tolerance by presenting “self-antigens” to naïve T- and B cells in a mature, but non-activated 
state
[72,74]
. 
 
1.4.2 Adaptive Immunity 
Although the innate immune system is able to clear most emerging infections before the onset 
of colonization, not all threats are recognized. This is due to the fact that pathogens co-
evolved and developed new ways of overcoming immunological barriers imposed on them 
throughout evolution
[49]
. To recognize unknown pathogen motifs, evolution has led to the 
formation of antigen receptors capable of sensing novel antigenic encounters. This is achieved 
through somatic recombination events on the genomic level. Variable (V), diversity (D), and 
joining (J) gene fragments encoding for these T- and B cell receptors are segmented and 
randomly assembled together with a fixed constant domain during cellular maturation events. 
This process, termed VDJ recombination, leads to a diverse repertoire of receptors with 
random but narrow specificities and is considered the hallmark of adaptive immunity
[75]
. 
The two major effector cell types comprising the adaptive immune system are B- and T-
lymphocytes. Both cell types are responsible for translating the peptide information acquired 
through professional antigen-presenting cells (APCs) into an effector immune response. 
B cells on the one hand produce a distinct type of immunoglobulin upon stimulation that 
solely depends upon the nature of the stimulus
[76]
. They mature in the bone marrow to ensure 
that “self”-reactive cells are not propagated in order to exclude potential auto-immune 
reactions. T cells mature to aid in adaptive immune responses through differentiating into 
several effector T-phenotypes (Th1, Th2, Th17, Treg)
[77,78]
. From the bone marrow, T cell 
precursors migrate into the thymus where they are either propagated or deleted from the 
functioning T cell pool to avoid “self” reactivity. This step is particularly important to ensure 
tolerance to “self” both in central as well as peripheral immunity[79,80]. After their selection 
process, both cell types migrate to secondary lymphoid organs where they reside as naïve 
cells within B- and T cell areas, respectively
[81]
. Upon contact with an activated APC 
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displaying a matching antigen for their specific B- or T cell receptor, cellular maturation is 
induced that results in the initiation of an appropriate adaptive immune response. 
It is important to note that B- and T cells recognize different forms of antigens. B cells on the 
one hand possess a membrane-bound immunoglobulin that is potentially targeted by foreign 
antigens, and thus, elicits activation of the respective B cell clone. The bound antibody on the 
surface of the B cell mimics a trans-membrane receptor and therefore is called B cell receptor 
(BCR)
[82]
. Once activated and matured into a plasma cell, the B cell is capable of releasing 
vast amount of soluble antibodies that possess the same specificity and binding affinity 
towards the initial activating antigen. In contrast to the T cell receptor (TCR), however, BCRs 
are able to bind soluble antigenic moieties presented to them via the lymph. Antigens 
presented to T cells through this route are not capable of eliciting cellular maturation and 
effector function unless accompanied by additional stimuli originating from professional 
APCs
[83]
. Furthermore, antigenic peptides loaded onto MHC molecules prior to extracellular 
presentation are cleaved within late endosomal structures of APCs. T cell maturation is only 
induced in the context of these structures in addition to discrete co-stimulatory molecules such 
as CD80 and CD86 that are sequestered or presented through APCs
[84]
. 
Unlike the innate immune response, information gathered in form of recognizable antigens 
has to be presented to effector cells in secondary lymphoid organs. Professional antigen-
presenting cells, which are responsible for the identification, storage and delivery of these 
antigens, pass on the acquired information via processed protein residues on MHC class I and 
II molecules acquired in peripheral organs
[85]
. Subsequently, (depending on the nature of the 
signal) a specific type of adaptive immune response is initiated in secondary lymphoid organs. 
Yet another hallmark of the adaptive immune system is the immunological memory. 
Infections that have been successfully cleared once lead to the formation of memory cells that 
store the antigenic information over a long period of time. If a given biological system is 
challenged with the same antigen again, re-activation of these dormant differentiated B cells, 
termed memory cells, lead to a rapid and enhanced immune response
[86]
. 
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1.5 Dendritic Cell Biology 
DCs represent professional antigen-presenting cells and are considered one of the most 
important immune cell types due to their pivotal role in determining the balance between 
immunity and tolerance induction
[87,88]
. Through their phagocytic and pinocytic activity, they 
are capable of ingesting vast amounts of extracellular material, including both self-antigens as 
well as foreign, potentially harmful, particles
[73,89]
. The capability for phagocytosis, 
macropinocytosis, and the expression of receptors mediating adsorptive endocytosis (e.g. C-
type lectin receptors and Fcγ and Fcε receptors) render DCs particularly effective in antigen 
uptake
[72,90,91]
. This also includes their expression of numerous receptors recognizing 
evolutionary conserved protein motifs on bacteria and viruses, such as TLRs
[92,93]
. 
DCs represent the most potent T cell activator, which provides them with the capability of 
initiating an appropriate adaptive immune response after antigenic contact. This is achieved 
through processing of antigens and presenting the acquired biological information to naïve T-
lymphocytes in the context of MHC molecules. Through the fusion process of phagosomes 
originating from endocytosed material with early lysosomes emerging from the endoplasmatic 
reticulum (ER), the invariant peptide chains of MHC II molecules are replaced with the 
appropriate foreign peptide chain (length 15-25 amino acids)
[94]
. Intracellular antigens 
originating from self-proteins or viral origin are processed in the cytosol and bind to MHC 
class I molecules directly for presentation on the cell surface
[95]
. The target for MHC I peptide 
presentation are CD8
+
 cytotoxic T cells, whereas MHC II loaded peptides confer activation of 
CD4
+
 helper T cells. The local cytokine milieu and co-stimulatory molecule expression on 
APCs polarizes naïve T cells toward an effector function (T helper (Th) 1, Th2, Th17 or 
regulatory T cells (Treg)) depending on the type and magnitude of the stimulus
[96]
. 
DCs that capture self-antigens in steady state are not being activated. Instead, presentation of 
acquired self-antigens leads to the maintenance of peripheral tolerance by silencing T cells 
potentially reacting against those antigens
[97,98]
. 
DCs are present primarily at sites of pathogen entry points such as skin, lung, and the 
gastrointestinal tract as well as in the circulatory system and internal organs, in particular 
lymphoid tissues
[72,91,99]
. 
Due to the fact that DCs are considered one of the most important cell type of the immune 
system, a lot of research has been devoted to understanding their biological function and 
origin
[89]
. It has been shown by several independent studies that DCs can be divided into 
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several subsets according to their localization, phenotype and function
[100]
. Both myeloid and 
lymphoid derived DCs originate from a common precursor within the bone marrow 
compartment expressing the receptor for fms-like tyrosine kinase 3 (Flt3)
[101,102]
. Asymmetric 
cell division events of Flt3
-
 HSCs result in Flt3
+
 progenitors capable of giving rise to both 
myeloid and lymphoid committed common progenitors that retain the potential to further 
differentiate into the various types of DCs (as previously depicted in Figure 1.1). 
The main DC subsets are non-lymphoid tissue migratory DC that are spread throughout 
peripheral organs, the conventional DCs (cDC) and plasmacytoid DCs (pDC) found in 
lymphoid tissue such as spleen and lymph nodes
[99,103]
. 
Interstitial DCs (DCs of e.g. dermis, mucosa and lung) and epidermal Langerhans cells (LCs) 
are both regarded as tissue DCs and represent the classical antigen presenting cells. In order 
for them to present antigens taken up and processed in the periphery, they constantly migrate 
from peripheral tissues via the lymphatics to draining lymph nodes
[104,105,106]
. Tissue DCs 
possess morphological characteristics such as membrane protrusions (dendrites) to constantly 
survey their immediate surroundings. After cellular activation due to antigen uptake, they 
acquire a migratory phenotype and present this immunological information to naïve T cells in 
lymphoid organs. Therefore, they are considered the true migratory DCs
[89]
. 
Due to different developmental origins and phenotypic characteristics, various subsets of 
tissue DCs have recently been studied in great detail. Especially skin DCs are well 
characterized and can be divided into epidermal LCs, CD103
+
Langerin
+
CD11b
low
 and 
CD11c
+
CD11b
+
 DCs of the dermis
[107,108,109]
. Similarly, DCs in other non-lymphoid tissues 
are classified into CD103
+
 and CD11b
+
 DCs
[110,111]
. 
Conventional DCs on the other hand reside within lymphoid organs and constantly monitor 
lymph-borne antigens. cDCs are also capable of initiating an adaptive immune response via 
the stimulation of lymphoid tissue resident naïve T cells. According to novel classifications, 
they can be subdivided into CD8α+ and CD8α- DCs[112,113]. The different cDC subsets have 
specialized functions, namely the ability to cross-present soluble and cell-associated antigens 
on MHC class I molecules to CD8
+
 T cells (CD8α+ DCs)[114,115] as well as presenting antigens 
on MHC class II to CD4
+
 T cells (CD8α- DCs)[116,117]. For this reason, CD8α+ and CD8α- 
cDCs display a distinct cytokine production repertoire to differentially regulate immune 
responses
[118]
. 
16 | I n t r o d u c t i o n  
pDCs are found in blood and in many organs such as the thymus, bone marrow and within T 
cell areas of lymphoid organs and possess a plasma cell-like phenotype in steady state
[119,120]
. 
They are involved in the recognition of viral infections and are known to produce vast 
amounts of type I interferons (IFN) upon stimulation. Activated pDCs are capable of priming 
T cells against viral antigens, although they are poor T cell activators compared to tissue DCs 
and cDCs
[121,122]
. 
Inflammatory DC (iDC) represent a specific DC subset that develop from circulating 
CD11b
+
Ly6C
+
CCR2
+
 monocytic precursors only under inflammatory conditions and that 
have no steady state counterpart. Amongst them are the so-called “tip-DCs” due to their 
potential to produce tumor necrosis factor α (TNFα), inducible nitric oxide synthase (iNOS) 
and oxygen radicals after microbial infection
[123]
. However, the exact function of 
inflammatory DC is still being elucidated, although they have been shown to be involved in 
antigen presentation to T cells or direct killing of pathogens
[41,124]
. 
 
1.6 Mechanisms of Endocytosis 
Endocytosis encompasses several diverse mechanisms by which cells internalize 
macromolecules and particles into transport vesicles derived from the plasma membrane 
through processes of engulfment, invagination and pinching. It controls entry into the cell and 
has a crucial role in development, immune responses, neurotransmission, intercellular 
communication, signal transduction, as well as cellular and systemic homeostasis
[125]
. Lipids, 
integral proteins and extracellular materials are transported to various intracellular 
compartments for further processing and recycling within the endosomal compartment
[126]
. 
Several forms of uptake are known that strongly depend upon particle size and antigenic 
surface makeup of the respective target cell and can be subdivided into two broad categories, 
phagocytosis and pinocytosis. Phagocytosis encompasses the uptake of larger structures and is 
usually confined to specialized cell types, whereas pinocytosis occurs in virtually all cells
[127]
. 
Pinocytosis includes four distinct mechanisms that depend on the size and structure of the 
ingested material: macropinocytosis (> 1μm), clathrin-mediated endocytosis (~ 120nm), 
caveolae-mediated endocytosis (~ 60nm), and clathrin- and caveolin-independent endocytosis 
(~ 90nm) (Figure 1.5)
[125]
. 
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The constitutively activated clathrin-mediated endocytosis (CME) permits the continuous 
uptake of nutrients by cells and the intercellular communication by rapid regulation of surface 
receptor levels. CME is also critically involved in serum homeostasis by regulating the 
internalization of membrane pumps that control the transport of small molecules and ions 
across the plasma membrane
[128]
. CME involves the concentration of high-affinity 
transmembrane receptors and their bound ligands into ‘coated pits’ on the plasma membrane, 
which are formed by the assembly of cytosolic coat proteins, the main assembly unit being 
clathrin
[129]
. Coated pits invaginate and pinch off to form endocytic vesicles that are 
encapsulated by a polygonal clathrin coat and carry concentrated receptor-ligand complexes 
into the cell. 
Caveolae-mediated endocytosis has been shown to be involved in the confinement of 
cholesterol and sphingolipid-rich microdomains of the plasma membrane, thereby 
contributing to overall lipid homeostasis
[130]
. 
Clathrin- and caveolin independent endocytosis are characterized by 40-50 nm cholesterol-
rich rafts. Their unique lipid composition provides a physical basis for specific sorting of 
membrane proteins and/or glycolipids based on their transmembrane regions
[131,132]
. These 
small rafts can presumably be captured by, and internalized within any endocytic vesicle. 
The second mechanism of endocytosis, namely phagocytosis, is involved in the clearing of 
pathogens, large debris and apoptotic cells
[133]
. Only professional phagocytes of the immune 
system such as monocytes, macrophages, and DCs are capable of employing this receptor-
dependent mechanism of uptake and subsequent signaling. This highly regulated process 
involves specific cell surface receptors with redundant and non-overlapping recognition 
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repertoires
[134]
, signaling cascades mediated by Rho-family GTPases and strong 
reorganization of the actin cytoskeleton
[135]
. 
 
1.7 Pathogen Recognition Receptor Repertoire of Immune Cells 
Pathogens are typically decorated by antibodies, complement factors, and mannose-binding 
lectin in a process called opsonization. In combination with PAMPs present on their surface 
structures, cell binding and pathogen uptake is facilitated. These processes are mediated by 
immunoglobulin receptors (FcRs), complement receptors, and the mannose receptor
[136]
. 
Furthermore, evolution has led to the formation of PRRs that are capable of recognizing 
evolutionary conserved structural motifs on i.e. bacteria and viruses
[43]
. These include 
scavenger receptors (SRs), lectins, and TLRs, that are capable of enhancing cellular binding 
and trigger a defined intracellular signaling cascade that initiates an appropriate 
immunological response
[92,137]
. Evolutionarily conserved receptors are widely expressed on 
virtually all immune cells. PRRs represent the arm of the innate immune defense system 
through sensing evolutionary conserved structures present on e.g. bacteria and viruses such as 
sugar residues, bacterial cell wall components, and DNA/RNA molecules. Up to now, four 
different classes of PRR families have been identified. These include transmembrane proteins 
such as the TLRs, C-type lectin receptors (CLRs), and cytoplasmatic proteins such as the 
retinoic acid-inducible gene RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs)
[138]
. 
The toll-like receptor family represents one of the best characterized PRR family. It 
recognizes a vast number of bacterial and viral protein moieties both on the cell surface and 
within confined endosomal vesicles. First discovered in Drosophila, the Toll protein was 
found in both immune and non-immune cells of vertebrates, including fibroblasts, epithelial 
and endothelial cells
[139]
. Each TLR recognizes its specific ligand(s) and has a specific sub-
cellular localization. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are located on the cell 
surface, whereas TLR3, TLR7, TLR8 and TLR9 are found in endosomal compartments 
(Figure 1.6)
[139,140]
. At least eleven members of the TLR family have been identified in 
mammals
[141]
. 
TLRs are characterized by N-terminal leucine-rich repeats and a trans-membrane region 
followed by a cytoplasmic Toll/IL-1R homology domain (TIR). All TLRs except TLR3 signal 
through a cardinal adaptor protein called myeloid differentiation primary response 88 
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(MyD88). TLR3, however, signals exclusively through the TIR-domain-containing adaptor 
inducing IFN-ß (TRIF) protein. TLR4, which mainly recognizes LPS, induces a dual 
signaling pathway involving both MyD88 and TRIF
[142,143]
. 
In innate immune cells, stimulation of TLRs activates transcriptional factors including NF-κB 
which results in morphological alterations, phagocytic respiratory burst, and up-regulation of 
co-stimulatory molecules and pro-inflammatory cytokines
[92,141]
. 
NLRs are the cytoplasmic counterparts of TLRs that recognize a set of cytosolic PAMPs and 
endogenous ligands and induce the activation of NF-κB in a TLR-independent manner[144,145]. 
Among the 14 members of NLRs belonging to the NACHT, LRR and PYD domains-
containing protein (NALP) family, NALP1 and NALP3 are the most significant. These NALP 
proteins contribute to the assembly of a structure termed inflammasome, which is crucial for 
the processing and activation of caspase-1
[146]
. NALPs regulate the production and release of 
IL-1ß, one of the most important pro-inflammatory cytokines, by recruiting the adaptor 
protein ASC (apoptosis-associated speck-like protein containing a CARD)
[147,148]
. It has been 
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shown that bacterial and viral RNA induce IL-1ß and IL-18 secretion in murine macrophages 
in a NALP3-dependent manner
[149,150]
. 
Cytoplasmic RIG-I-like RNA helicase (RLH) receptors are involved in TLR-independent 
recognition of dsRNA, which results in activation of IRFs and NF-κB transcription factors[151]. 
The RIG-I receptor recognizes the 5’-triphosphate terminus of viral RNA that is usually 
capped by adding 7-methylguanosine during posttranslational RNA modifications in 
eukaryotes
[152]
. Therefore, “self” RNA does not trigger receptor detection[153]. 
Through the aid of these various PRRs, immune cells are capable of “sensing” foreign or 
potentially harmful structural moieties and initiate appropriate counter-measures. It can be 
envisioned that exogenous substances such as magnetic nanoparticles employed in molecular 
imaging techniques are detected in similar ways. Furthermore, surface functionalization 
responsible for the recognition, subsequent cellular uptake and vector accumulation within 
target tissues are designed to fulfill a specific imaging or treatment goal. Therefore, modern 
research aims at endowing imaging or therapeutic probes with recognizable surface ligands. 
These structures either mimic PRR ligands or are designed to avoid cellular uptake that leads 
to prolonged circulation times through evading immune detection, and thus, allow enhanced 
imaging. 
 
1.8 Nano-Bio Interface(s) 
Recently, interdisciplinary research has been evaluating the possible impacts of various 
interfaces that emerge at the intersection of nanoparticles and biological entities such as media 
and cellular membrane structures
[154]
. Most importantly, it is believed that these interfaces 
alter the properties of the MNP being employed, including overall size and surface properties 
due to protein absorption and resorption effects. The nano-bio interface comprises three 
dynamically interacting components, namely (i) the nanoparticle surface, which 
characteristics are determined by its physico-chemical composition, the (ii) solid-liquid 
interface and the changes that occur when the particle interacts with components present in 
the surrounding medium, and (iii) the solid-liquid interface contact zone with biological 
substrates or structures of cellular membranes (as illustrated in Figure 1.7)
[155]
. 
The basis of the underlying forces ultimately resulting in a change of surface parameters on 
MNP formulations rely on physico-chemical molecule interactions between particle shell 
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components, soluble proteins and other reactive molecules. Van-der-Waals, electrostatic, 
solvation, solvophobic and depletion forces are considered to be critically involved in this 
context
[156]
. However, the sum of interaction forces is subject to change depending on 
temporal interaction kinetics, fluid mechanics and molecular localization patterns
[157]
. 
Understanding these physical and chemical properties is crucial when optimizing contrast 
agents for molecular imaging techniques in the future. Targeted approaches solely rely on the 
surface characteristics of employed nanomaterials to be interacting with designated target 
structures on specialized cell types or tissue components. Therefore, nanoparticle surface 
characteristics have to be designed accordingly to either (i) evade the formation of protein 
soft-shells around MNP formulations that could potentially shield reactive sites important for 
cellular recognition and uptake, or (ii) exploit protein adhesion through promoting the binding 
of specific soluble factors beneficial for subsequent cellular and/or tissue accumulation. 
“Stealth” particles covalently decorated with molecules such as PEG have been shown to 
avoid protein accumulation around contrast agents whilst in circulation, and thus, extend half-
life and imaging times during MRI scans
[12,158]
. On the other hand, MNPs being opsonized by 
the actions of serum constituents are cleared from the biological system rather quickly, thus 
reducing both vector accumulation times and resulting imaging performance
[159]
. 
However, scientists are just beginning to fully comprehend the mechanisms involved in 
particle decoration, resulting alteration of designed MNP properties, and the modified cellular 
interactions resulting as a consequence
[156,160]
. Further knowledge has to be attained to ensure 
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MNP functionality, and consequently, imaging characteristics to further improve medical 
diagnosis and treatment in the future. 
 
1.9 Aim of the Study 
Engineered magnetic nanoparticles are currently emerging as promising tools in numerous 
applications for medical therapy and diagnostics including the development of drug delivery 
systems and contrast agents for magnetic resonance imaging. In vitro labeling of target cell 
populations with MNPs before therapeutic implantation shows great promise in monitoring 
successful cell engraftment, differentiation and migratory behavior using MRI. Depending on 
the desired therapeutic treatment outcome, these biological processes remain critical for the 
success of such cell-based therapies. 
Hematopoietic stem and their derived precursor cells are particularly effective targets for cell-
based therapies due to their plasticity and ability to reconstitute the entire cell pool of the 
hematopoietic system in both steady-state and disease. On the other hand, terminally 
differentiated immune cells represent optimal labeling agents due to their potential to initiate 
appropriate immune responses within the host. In combination with molecular probes, these 
cells are already being used in clinical research applications. However, the principles 
governing cellular interactions with MNPs that lead to the recognition, subsequent uptake and 
resulting imaging properties are largely unknown. 
Therefore, the primary objective of this study was to investigate uptake characteristics of 
synthetic MNPs of various origins and surface modifications into HSCs and their downstream 
effector cells including DCs and macrophages. This included LbL-synthesized nanoparticles, 
lipid-shell coated MNPs, covalently functionalized and biogenic magnetosome MNPs. 
Through altering chemical properties of employed MNPs such as overall particle size, surface 
charge, and shell chemistry, a solid experimental platform was generated to study the 
involvement of these parameters in the context of cellular interactions and subsequent uptake 
processes. Since MRI properties are based on the capacity of MNPs to alter their immediate 
proton environment, TEM studies of labeled immune cells were performed prior to assessing 
contrast agent potential using MRI. 
Immunogenicity of medical probes such as MNPs remains of great interest to current research. 
Shaping reactive MNP moieties to confer (i) receptor-mediated uptake and subsequent 
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signaling, or (ii) evasion of clearance mechanisms represent powerful tools to enhance 
imaging and targeting of specialized cell types or tissues in both health and disease. To 
address these concepts, possible PRR involvement in the recognition and signaling after MNP 
exposure was addressed through employing discrete knockout models. Phenotypic alterations 
arising as a direct consequence of particle uptake were investigated through assessing both the 
cell surface molecule repertoire as well as the release of pro-inflammatory cytokines, which 
both represent a direct consequence of primary immune reactions. 
We expect these findings to be highly valuable in understanding MNP-cell interactions that 
ultimately shape molecular imaging characteristics. 
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2 Materials and Methods 
 
2.1 Materials 
2.1.1 Cell Culture Media and Supplements 
2.1.1.1 Cell Culture Media 
If not otherwise indicated, all cell culture media were purchased from Invitrogen. 
Basic DC and splenocyte growth medium: 
RPMI 1640 containing 2 mM l-glutamine, 100 U/ml penicillin, 10 µg/ml streptomycin (all 
Invitrogen), 50 µM β-mercaptoethanol (Sigma-Aldrich), and 10% FCS (PAA, heat inactivated 
for 20 min at 42°C (core temperature)). 
Basic macrophage growth medium: 
DMEM containing 100 U/ml penicillin, 10 µg/ml streptomycin, 50 µM β-mercaptoethanol, 
and 10% heat-inactivated FCS. 
Serum-free DC medium: 
Gibco Macrophage-SFM medium supplemented with 100 U/ml penicillin, 10 µg/ml 
streptomycin. 
 
2.1.1.2 Growth Factors 
Growth factor  Source 
GM-CSF, murine Peprotech, Produced in E. coli in house or purchased 
from Pharmedartis GmbH, Aachen *
1
 
IGF-1, long range human Sigma-Aldrich 
IL-6/IL-6 receptor fusion protein provided by S. Rose-John, Kiel  
M-CSF, human Peprotech 
SCF, murine recombinantly produced in CHO cells *
2
 
Dexamethasone Sigma-Aldrich 
Flt3L, human Peprotech 
 
*
1
 Using plasmid pETH2aHISmGM-CSF (S.M. Kurz, PhD thesis, 2000). 
*
2
 Using the pETH2a HIS-mSCF plasmid (S.M. Kurz, PhD thesis, 2000). 
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2.1.2 Mice 
C57BL/6 Wt and MyD88
ko
 mice were bred and maintained under specific pathogen free 
conditions in the central animal facility of the University Hospital, Aachen, Germany.  
MyD88
ko
, ASC
ko
, TLR4
ko
, and TLR9
ko 
were bred and maintained under specific pathogen 
free conditions in the World Premier Institute IFReC, Osaka, Japan. Mice used for 
experiments were between 7-14 weeks of age. All animal experiments were approved by local 
authorities in compliance with the German or Japanese animal protection law. 
 
2.2 Methods 
2.2.1 Cell Culture of Primary Cells 
All primary cell types were grown in a humidified incubator at 37°C and 5% CO2 under 
sterile conditions. Aseptic methods as well as good laboratory practice were employed at all 
times to avoid possible contaminations that might potentially alter experimental outcomes. 
 
2.2.1.1 Isolation of Murine Bone Marrow Cells 
Bone marrow cell suspensions were prepared from femur and tibia of mice. Animals were 
anesthetized and sacrificed using cervical dislocation and incisions were made into the 
abdominal skin to expose hind legs. Muscle tissue was removed from bones using mechanical 
force and gentle scraping. Aseptic removal and disinfection of relevant bones with 70% EtOH 
was performed prior to flushing the red marrow using a 23G needle with basic growth 
medium. This process was repeated several times prior to washing twice using growth 
medium to obtain a homogenous single cell suspension of bone marrow cells. Cell numbers 
were counted employing an electronic counting device (CASY 1, Roche) and stored until 
further experimental procedures. 
 
2.2.1.2 Culture of GM-CSF derived Progenitors and iDCs 
After explantation, progenitor cells were seeded into 100 mm cell culture plates (Nunc) using 
a concentration of 2x10
6 
cells/ml in basic DC growth medium supplemented with 30 U/ml 
muSCF, 5 ng/ml hyperIL-6, 25 ng/ml Flt3L, 40 ng/ml huIGF-1 long range, 25 U/ml muGM-
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CSF, and 1 µM Dexamethasone
[101]
. After three days of culture, a Ficoll-Hypaque density 
gradient centrifugation (PAA, density 1.077 g/ml) was performed to remove dead cells and 
debris from the culture. Complete exchange of growth medium was carried out every second 
day thereafter employing basic DC growth medium with supplemented growth factors 
outlined above until differentiation was initiated. Depending on experimental endpoint studies 
and cell numbers required, differentiation was initiated on day 5-9 of amplification. For this 
purpose, basic DC growth medium supplemented with 200 U/ml muGM-CSF was used. Cells 
were counted and seeded as before, replenishing medium and adjusting cell concentration to 
2x10
6 
cells/ml. Differentiation medium was exchanged every second day thereafter as 
previously outlined. Cytometric analyses were performed to consistently monitor 
differentiation status of cells throughout the differentiation period until immature iDC 
phenotype was acquired on day 7-9. Endpoint experiments were conducted accordingly. 
 
2.2.1.3 Culture of Flt3L derived Progenitors and cDCs/pDCs 
Following explantation from the bone marrow, progenitor cells were seeded into 100 mm 
plates (Nunc) at a final concentration of 2x10
6 
cells/ml in a volume of 10ml using basic DC 
growth medium supplemented with 30 U/ml muSCF, 5 ng/ml hyperIL-6, 25 ng/ml Flt3L, and 
40 ng/ml huIGF-1 long range
[161]
. After three days of culture, a Ficoll-Hypaque density 
gradient centrifugation (PAA, density 1.077 g/ml) was performed to remove dead cells and 
debris from the culture. Complete exchange of growth medium was performed every second 
day thereafter employing basic DC growth medium with supplemented growth factors 
outlined above until differentiation was initiated on day 7 of culturing. For this purpose, 
Flt3L-derived progenitors were seeded into 6-well plates on day 0 of differentiation using a 
concentration of 1x10
6
 cells/ml (2 ml final volume) in basic DC growth medium 
supplemented with 100 ng/ml Flt3L
[161]
. Differentiation medium was partially exchanged 
without disturbing cell clusters on day 3 and 5 of culturing. Phenotypic progression was 
monitored using FACS starting on day 5 of culturing. On day 7, cells were pooled and seeded 
into appropriate culture dishes prior to experimental stimulation. Experimental endpoint 
studies were carried out on day 8 accordingly. 
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2.2.1.4 Cell Culture of Macrophages 
1-step bone marrow derived macrophages were cultured in the presence of M-CSF. Isolation 
of bone marrow progenitor cells was conducted as outlined in 2.2.2.1. No Ficoll density 
gradient was performed on day 3 of culture due to adherently growing target cells and lack of 
amplification period in this culturing system. Instead, red blood cell lysis was carried out after 
obtaining single cell suspensions from bone marrow explants according to manufacturer’s 
guidelines (ACK Buffer, Lonza) after explantation. Subsequently, cells were seeded at 1x10
6 
cells/ml in a total volume of 2 ml of basic macrophage growth medium supplemented with 20 
ng/ml human M-CSF onto 12-well plates. Macrophage growth medium was exchanged 
without disturbing adherently growing cells on day 3 and 5 of culturing. On day 5, cells were 
gently flushed twice using 1 ml of PBS to remove loosely attached and suspending cells 
(unwanted DC precursors) prior to the addition of supplemented macrophage growth medium 
as previously outlined. On day 7, cells were washed again using PBS and resuspended in 
macrophage growth medium in addition to stimulating the bulk culture with MNPs and 
respective controls. Cells remained in identical plastic dishes during the entire course of 
differentiation to avoid growth delays and potential cell death arising as a result of dislodging 
and re-seeding of adherently growing cells. Prior to gentle cell detachment using acutase 
(Millipore) according to manufacturer’s guidelines on day 8, cell supernatant was collected 
and frozen for further ELISA studies. To ensure the completion of the dislodging process, 
cells were periodically monitored under the microscope until all cells were in suspension. 
Macrophages were washed twice with growth medium to terminate the action of acutase. 
Cytometric evaluation of macrophage lineage and activation markers was performed 
thereafter. 
 
2.2.1.5 Explantation and Culture of Primary Splenocytes 
Animals were sacrificed employing cervical dislocation after being anesthetized. Spleen was 
carefully explanted without compromising organ integrity. After explantation, spleen tissue 
was mechanically dissociated and passed through a 70 µm cell strainer to exclude connective 
tissue. To obtain a single cell suspension thereafter, cells were repeatedly passed through a 
23G needle and washed several times in washing buffer (PBS + 2% FCS) before red blood 
cell lysis was performed according to manufacturer’s guidelines (ACK Buffer, Lonza). After 
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several washing steps using basic DC growth medium, cells were kept at +4°C until further 
experimental procedures. 
 
2.2.2 Nanoparticle Synthesis and Characterization 
2.2.2.1 Synthesis of Poly-Electrolyte coated MNPs 
Poly-electrolyte MNPs were all designed and synthesized using Layer-by-Layer technologies 
in the Institute of Physical Chemistry, RWTH Aachen, Germany. Experimental procedures 
were carried out by Wong and co-workers as outlined in the following sections
[162]
. 
 
2.2.2.1.1 MNP Core Synthesis 
In order to synthesize MNP core structures, the following adapted co-precipitation technique 
was employed. A Fe
3+
 solution was prepared by dissolving 4.86 g ferric chloride hexahydrate 
(FeCl3·6H2O, Sigma-Aldrich) in 30ml distilled water as well as preparing an Fe
2+
 solution by 
dissolving 2.98 g ferrous chloride tetrahydrate (FeCl2·4H2O, Sigma-Aldrich) in a mixture of 
10ml water and 1.5 ml 37% hydrochloric acid. Both solutions were placed in an ultrasonic 
bath for 5min to homogenize the mixture. The Fe
3+ 
and Fe
2+ 
solutions were then mixed and 
allowed to stand in the ultrasonic bath for 2 min just prior to precipitation. To precipitate the 
iron oxide, the resulting mixture of Fe
3+ 
and Fe
2+ 
was added drop-wise to a flask containing 
240 ml water and 60 ml 25% NH3 under vigorous stirring (500 rpm). A black suspension was 
formed immediately and MNP formation was allowed to proceed for 30 min at RT with 
constant stirring to produce a stable, water-based suspension. Aggregates were first separated 
from the reaction mixture using a strong magnet, and subsequently washed three times with 
0.3M NH3 solution. The washed precipitate was peptized by washing twice with 60 ml of 2M 
HNO3 solution. Peptizing is the process by which anionic charges on the nanoparticle surface 
are neutralized. Three cycles of centrifugation at 5000 rpm for 10 min were carried out and 
the precipitate dissolved in 120 ml of ddH2O water to yield a stable ferrofluid. Exposure of 
this ferrofluid to a magnetic field revealed no phase separation, confirming a complete re-
dispersion. This unmodified MNP is positively charged. 
Furthermore, MNPs on the basis of the fluidMAG technology were employed to serve as core 
particle structures in subsequent coating steps (kind gift from ChemiCell GmbH). Negatively 
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charged fluidMAG-PAS (carboxylated (COO
-
) terminal groups) and fluid-MAG-PS 
(sulfonated (SO
3-
) terminal groups) were employed in coating strategies using positively 
charged polymers. On the other hand, positively charged fluidMAG-Q (terminal amino 
(R4N
+
) groups) and fluid-MAG-UC/C (cationic (O
+
) terminal groups) MNPs were used in 
case of negatively charged poly-electrolyte coating strategies. 
 
2.2.2.1.2 LbL Assembly of Poly-Electrolytes around Fe Cores 
Layer by layer technology was adopted to deposit opposingly charged layers of poly-
electrolytes onto charged core MNPs previously discussed. Positively charged MNPs were 
coated with poly(styrene sulphonate) (PSS, MW 70 kDa, Sigma-Aldrich) and negatively 
charged MNPs were modified with poly(diallyldimethylammonium chloride) (PDAD, MW 
100-200 kDa, Sigma-Aldrich) or poly(ethyleneimine) (PEI, MW 750 kDa, Sigma-Aldrich). In 
principle, 20 ml of a 1:100 diluted dispersion of MNPs (either positively or negatively 
charged) was added to 40 ml of an aqueous solution (conc. 1 g/l) of the oppositely charged 
polyelectrolyte to prepare the initial layer. The solution was first allowed to mix in an 
ultrasonic bath for 30 min. To ensure that saturation adsorption of the poly-ions on the colloid 
particles was reached, additional incubation for 12 h was performed. The products were 
separated from the excess poly-electrolyte twice through magnetic separation. The precipitate 
was briefly subjected to an ultrasonic treatment to yield a stable solution. 
Dextran sulfate (Dex, MW 100 kDa, BioChemica) and chitosan (Chit, MW 50-190 kDa, 85% 
deacetylated, Sigma-Aldrich) represent weak poly-electrolytes, whose degree of charge can 
be varied according to the pH. Dextran (pKa ~ 4.0) was diluted in an aqueous solution 
without pH adjustment (pH ~ 6), thereby ensuring its negative charge. Chitosan is a cationic 
polymer containing 15% N-acetyl-D-glucosamine. A solution was obtained by dissolving 
chitosan in an aqueous solution of 25% acetic acid (pH ~ 1.3). The pKa of chitosan is ~ 6.0, 
ensuring that the chitosan prepared is positively charged and thus endows MNPs with a 
positive surface layer. LbL assembly of dextran and chitosan was performed just as described 
for the synthetic poly-electrolytes
[162]
. 
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2.2.2.2 Oleate-Stabilized MNPs 
Lipid shell MNPs employing sodium oleate as stabilizing shell component were designed and 
synthesized in the Institute for Applied Medical Engineering (AME), RWTH Aachen, 
Germany. Superparamagnetic magnetite lipid–shell core MNPs were obtained by co-
precipitation of Fe
2+
 and Fe
3+
 ions with NH3. Stabilization was achieved using cis-9-
octadecenoic acid sodium salt (oleate). Experimental procedures were carried out by 
Hodenius and co-workers as outlined in the following sections
[163]
.  
 
2.2.2.2.1 Synthesis of Fe Core Particles 
Initial core particle synthesis followed a technique previously published by Khalafalla and 
Reimers
[164]
. 8.25 ml starting volume of an aqueous solution that contains 2 g FeCl3 x 6H2O 
(7.5 mmol) and 1 g FeCl2 x 4H2O (5 mmol) resulted in a Fe
3+
/Fe
2+
 molar ratio of 3/2. 
Subsequently, 4.18 ml of a 25% NH3 solution was added drop-wise at RT under continuous 
stirring. Iron oxide was formed immediately, resulting in a black, magnetizable suspension. 
The reaction mixture was stirred for an additional 5 min to allow completion of the reaction. 
The black precipitate was separated from the clear supernatant by magnetic decantation. 
 
2.2.2.2.2 Oleate-stabilized Ferrofluids 
After removal of the excess chloride ions, stabilization of the individual iron oxide cores was 
achieved through peptization using cis-9-octadecenoic acid sodium salt (oleate). In practice, 
0.75 g sodium oleate (2.5 mmol) was added to the iron oxide precipitate, heated to 90°C, 
while stirring with a glass rod for 5 min. After peptization with oleate, transformation of the 
iron oxide cores into colloidal particles of ferrofluid was completed by a sonication treatment 
(titanium probe-tip sonicator UP 200 S, Hielscher). 
 
2.2.2.3 Bacterial Magnetosomes 
Magnetosomes were isolated and purified from an actively growing magnetotactic bacterial 
strain Magnetospirillum gryphiswaldense MSR-1 (DSM6361) by Schueler and colleagues in 
the Institute of Microbiology, LMU, Munich, Germany. Experimental procedures followed a 
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protocol previously described by Gruenberg et al.
[165,166]
. The strain was grown under 
microaerobic conditions in an oxystat fermentor. 
Experimental conditions used to isolate magnetosomes followed the protocol previously 
described, with minor modifications. Briefly, 10 g (wet weight) of M. gryphiswaldense cells 
suspended in 50 ml of 50 mM HEPES – 4 mM EDTA (pH 7.4) was disrupted by three passes 
through a French pressure cell (20000 lb/in
2
). All buffers used for magnetosome isolation 
contained 0.1 mM phenyl-methyl-sulfonyl-fluoride (PMSF) as a protease inhibitor. Unbroken 
cells and cell debris were removed from the sample by centrifugation (5 min, 680 x g). The 
cell extract was passed through a MACS magnetic separation column (Miltenyi). Columns 
were placed between two Sm-Co magnets, which generated a magnetic field that magnetized 
the column wire matrix and produced strong magnetic field gradients near the wires that 
resulted in entrapment of the magnetic particles. Bound magnetic particles were initially 
rinsed with 50 ml of 10 mM HEPES – 200 mM NaCl (pH 7.4) followed by 100 ml of 10 mM 
HEPES (pH 7.4). After removing the column from the magnet, magnetic particles were eluted 
from the column by flushing with 10mM HEPES buffer. Finally, the magnetosome 
suspension was loaded on top of a sucrose cushion (55% (wt/wt) sucrose in 10mM HEPES 
(pH 7.4)) and subjected to ultracentrifugation in a swinging bucket rotor. The pellets were 
analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) after extensive washing and re-
suspended in buffer solution and stored under N2 atmosphere until further use. 
 
2.2.2.4 Synthesis of Covalently linked “Stealth” MNPs 
Covalently linked “stealth” particles were designed and synthesized in the Department of 
Nanobiotechnology, Laboratory for Supramolecular Materials, ETH Zurich, Switzerland. 
Additional details of the experimental design used to generate particle formulations have been 
published in Amstad et al., 2009
[167,168,169]
. 
 
2.2.2.4.1 Synthesis of Iron Oxide Core MNPs 
To synthesize iron oxide MNPs by aqueous precipitation methods the protocol established by 
Massart was followed
[170]
. A typical batch was synthesized out of 198.8 mg (1.2 mmol) FeCl2 
and 540.6 mg (2.3 mmol) FeCl3. Black precipitates indicated the immediate iron oxide MNP 
formation after the pH was shifted >10 using concentrated NaOH. The resulting MNPs were 
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neutralized through washing with 10 mM HEPES solution. To accelerate MNP agglomeration 
especially at high pH used to electrostatically stabilize MNPs, 160 mM NaCl was added to the 
HEPES buffer. 
 
2.2.2.4.2 Synthesis of Anchor Moieties and Functional Groups 
Synthesized core MNPs were stabilized within 4 h after the synthesis was completed. To a 
typical batch of iron oxide MNPs obtained from 1.2 mmol FeCl2 and 2.3 mmol FeCl3, 24 
mmol of PEG(0.55)-gallol or PEG(5)-gallol dissolved in 25 ml Millipore water was added. 
MNPs were dispersed in this solution by pulsed sonication (5 min, P = 10
5 
/ cm
2
, pulse 
frequency = 1 s on, 1 s off, UP260s, Hierschler GmbH). To stabilize MNPs with a mixture of 
biotin-PEG(3.4)-gallol and mPEG(0.55)-gallol, 25 ml Millipore water containing 2.4 mmol of 
the former dispersant was added to uncoated MNPs before they were sonicated and back-
filled with 21.6 mmol mPEG(0.55)-gallol. MNPs were sonicated a second time according to 
the above described procedure. Excessive dispersants were removed by ultracentrifugation 
using a filter with a cut-off of 30 kDa (vivaspin, Epson). The filter cake was re-suspended in 
Millipore water before the dispersion was freeze-dried. MNPs were re-suspended in PBS, 
HEPES or Millipore water, sonicated for 30 min, and centrifuged for 10 min at 25000 x g 
(Eppendorf centrifuge 5417R) to eliminate agglomerates. The dispersed MNPs in the 
supernatant were freeze-dried a second time. 
Since especially PEG-based dispersants are poorly soluble in EtOH, they were first aliquotted 
in DMF at a concentration of 100 mg/ml. This dispersant solution was pipetted into an 
eppendorf tube containing EtOH or DMF, respectively, before the MNP dispersions were 
added. MNPs were stabilized at 50°C for 24 h under constant mechanical stirring. MNPs 
which were functionalized e.g. with biotin or acrylate terminated dispersants were first 
incubated with the functionalized dispersants (10 mol % unless stated otherwise) at 50°C for 
30min under constant mechanical stirring at 500 rpm. Un-functionalized dispersants were 
added to this dispersion and MNPs were incubated for another day at 50°C under constant 
mechanical stirring at 500 rpm. To exchange EtOH with water and to partially remove 
excessive dispersants, stabilized MNPs were dialyzed for 24 h against Millipore water. 
Approximately 5 ml MNP dispersion was dialyzed against 50 ml Millipore water and the 
Millipore water was exchanged twice. Fe3O4 MNPs synthesized were dialyzed using 14-16 
kDa cut-off dialysis tubings (Spectra/Por dialysis membrane, spectrum labs). 
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Synthesized MNPs were stabilized within 6 h after the MNP synthesis was completed. 6 mg 
palmityl-nitroDOPA dissolved in DMF at a concentration of 100 mg/ml was added to 0.5 ml 
EtOH before 0.5 ml of the Fe3O4 MNPs synthesized was added. Palmityl-nitroDOPA was 
adsorbed for 24 h at 50°C under constant mechanical stirring at 500 rpm (Thermomixer 
comfort, Vaudaux-Eppendorf). To remove excessive dispersants, MNPs were washed three 
times by centrifugation for 30 min at 14000 rpm before the supernatant was exchanged with 1 
ml fresh EtOH. MNPs were centrifuged a fourth time where EtOH was exchanged with 1 ml 
Millipore water before these MNPs were freeze-dried. 
Acrylated MNPs were functionalized similar to biotinylated MNPs. Briefly, iron oxide core 
particles (synthesized as previously described herein) were stabilized with 10 wt% (0.6 mg 
dispersant per mg MNP) acrylate-PEG-nitroDOPA in EtOH at 50°C for 30 min prior to back-
filling using 90 wt% (5.4 mg dispersant per mg MNP) mPEG-nitroDOPA. Dispersants were 
adsorbed onto the MNP surface for 24 h and washed thereafter employing dialysis and 
centrifugation as previously outlined before freeze-drying MNPs for further use. A 1:1.5 
molar ratio of MNP to CpG was finally used to functionalize acrylated MNP moieties. 
Particles and CpGs were mixed and incubated at 30°C for 24 h. Magnetic separation at 4°C 
for additional 24 h was employed thereafter to purify particle solutions. The resulting clear 
supernatant containing Millipore water and unbound CpG was carefully removed and an 
equal amount of fresh H2O was added prior to resuspending particles. This washing process 
was repeated a total of three times. 
 
2.2.2.5 MNP Characterization 
The zeta (-) potential and hydrodynamic diameter (Dh) of MNP formulations were measured 
and calculated by cumulant fits using a Zetasizer 3000HS (Malvern) at 25°C with a dilute 
dispersion of the MNP in pure water. 
 
2.2.3 Cell Labeling with MNPs 
Sterile solutions of MNPs were sonicated for 30 min prior to cell labeling and used at a final 
iron concentration of 10 g/ml if not otherwise indicated. DC subsets were seeded at 2x106 
cells/ml and incubated with respective MNPs for 24 h. In case of adherently growing 
macrophage populations, semi-confluent dishes were labeled on day 7 of culturing, 
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corresponding to approximately 80% of confluence. 1x10
6
 explanted mixed splenocytes were 
labeled in a total volume of 1ml. Cells were harvested by gentle pipetting and subsequent 
centrifugation (1400 rpm, 4 min) and washed in PBS containing 2% FCS for further 
experimental procedures. In case of macrophages, adherent cell populations were gently 
dislodged after incubation time using acutase as previously described. 
 
2.2.4 MACS Cell Sorting 
MNP-labeled cell populations were subjected to magnetic separation to evaluate uptake 
properties (MACS, Miltenyi Biotech) as previously reported
[171,172]
. After 24 h of MNP 
exposure, cells were extensively washed twice in MACS buffer (PBS + 2% FCS) to remove 
unbound particles from suspension prior to their application onto magnetic columns. Cells 
were resuspended in 1 ml of buffer and gently applied to magnetic columns. Columns were 
subsequently washed twice using 500 µl of buffer solution containing unlabeled cell 
population. Retained cell fraction was subsequently eluted employing MACS buffer using 
mechanical force after removal of the magnetic field. This step was performed twice using 
500 µl for each elution step. Both fractions were counted using a cell counting device (CASY 
1, Roche) and stored at 4°C until further use. 
 
2.2.5 Cell Viability Assays after MNP Exposure 
2.2.5.1 MTT Assay 
Cytotoxicity of MNP labeled bulk cultures was evaluated using a photometric MTT assay. 
Progenitors and differentiated DCs were seeded in 24-well plates at a concentration of 1x10
5
 
cells/ml and incubated with MNPs for 24 h. To assess cell viability, MTT reagent (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma-Aldrich) was added to cell 
culture for an incubation period of 3 h according to the manufacturer’s protocol (Sigma-
Aldrich). To dissolve resulting crystal structures otherwise interfering with subsequent 
photometric analyses, MTT solubilizing solution (10% Triton X-100 plus 0.1 N HCl in 
anhydrous isopropanol) was added. After dissolving crystals through rigorous pipetting, 
absorbance was measured at 570 nm (FLUOstar OPTIMA, BMG Labtech). 
 
M a t e r i a l s  a n d  M e t h o d s | 35 
 
2.2.5.2 Flow Cytometric Analysis (FACS) employing 7-AAD  
In order to investigate cytotoxicity of MNP formulations within labeled cell fractions alone, 
fluorescent 7-AAD (7-amino-actinomycin D) stainings were employed. In brief, 2x10
5
 cells 
were washed with PBS after incubation with respective MNPs and incubated with 50 ng/ml 7-
AAD (eBioscience) for 20 min at +4°C in the dark in a total volume of 50 µl. After additional 
washing in PBS to remove unbound dye, cells were analyzed by flow cytometry as described 
in 2.2.9. Untreated cells as well as positive controls treated with 0.3% H2O2 for 30 min were 
included in the studies. 
 
2.2.6 FerroZine Iron Assay 
Intracellular iron concentration was determined using a colorimetric ferrozine iron assay as 
previously described
[171,173]
. Briefly, 1x10
6
 DCs were lysed in 100 l 50 mM NaOH. 100 l of 
a 10 mM HCl solution was added to neutralize alkaline pH. Subsequently, 100 l of freshly 
prepared iron releasing agent consisting of 1.4 M HCl and 4.5% (w/v) potassium 
permanganate (KMnO4) was added. The resulting suspension was thoroughly mixed and 
incubated for 2 h at 60°C under constant shaking. After cooling to RT, 30 l of iron detecting 
agent (6.5 mM ferrozine, 6.5 mM neocuproine, 2.5 M ammonium acetate, and 1 M ascorbic 
acid (all from Sigma-Aldrich)) was added and incubated for 30 min at RT under constant 
shaking. Ascorbic acid is used to reduce Fe
3+
 to Fe
2+
 ions that form a chelate with ferrozine 
(3-(2-pyridyl)-5,6-bis(phenyl sulfonic acid)-1,2,4-triazine; Sigma-Aldrich). Neocuproine 
scavenges copper ions that otherwise interfere with subsequent reactions. 280 l were 
pipetted into 96-well plates (Greiner, flat-bottom) and absorbance of Fe
2+
-ferrozine was 
measured at 550 nm (FLUOstar OPTIMA, BMG Labtech) and compared to the absorbance of 
FeCl3 standards. The minimum detection limit for Fe
2+
 ions was 250 mol/l, corresponding to 
5 pg of iron per cell. 
 
2.2.7 Prussian Blue Staining 
To visualize total iron uptake, 1x10
5
 cells labeled with MNPs were centrifuged (4 min at 1500 
rpm) onto a glass slide using a cytospin centrifuge (Thermo Fisher Scientific). After washing 
in double-distilled (dd) H2O, glass slides were subjected to Prussian blue staining using a 1:1 
solution (v/v) of 10% potassium ferrocyanide K4[Fe(CN)6] (Sigma-Aldrich) and 20% HCl for 
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20 min. After washing in ddH2O, glass slides were counter-stained with Neutral Red dye 
(Roth) for 5 min and mounted with cover slips using mounting medium (Dako). Sample 
images were obtained using a Leica DM6000B microscope (Leica) and Diskus acquisition 
software (Hilgers). Images were processed using Adobe Photoshop and ImageJ. 
 
2.2.8 Transmission Electron Microscopy (TEM) 
Transmission electron microscopy was performed in collaboration with the TEM Facility of 
the Institute of Pathology at the RWTH Aachen. Briefly, 1x10
6
 magnetically sorted DCs were 
fixed with 3% (w/v) glutaraldehyde and embedded in 2% agarose. Samples were stained with 
OsO4, embedded in Epon and cut into 70 nm thick slices. Samples were either analyzed with 
or without further contrast enhancement using a Philips EM 400T electron microscope at 60 
kV equipped with a CCD camera (MORADA, Olympus). 
TEM images were analyzed using NIH ImageJ software. Electron densities of MNP-
containing sub-cellular compartments were calculated from pixel intensities within defined 
regions of interest (ROIs) obtained in ImageJ. Normalized values were calculated as 
(signalMNP – signalBackground) x areaROI [nm
-2
]. A total of 30 different MNP-containing areas 
within compartmental structures were evaluated. 
 
2.2.9 Phenotypic Analysis using FACS 
Flow cytometry was used to analyze cellular phenotype prior to and after experimental 
procedures. Single cell suspensions from different sources (bone marrow, spleen, cultured 
cells) were prepared for flow cytometry through extensive washing and re-suspension in 
FACS staining buffer (PBS supplemented with 2% FCS) prior to staining. Approximately 
2x10
5
 cells were then incubated with the respective antibody combination in a volume of 50 
µl for 30 min at +4°C in the dark. After repeated washing using FACS staining buffer, cell 
pellets were resuspended in 200 µl prior to experimental endpoint studies. Stained cells were 
analyzed employing FACS Calibur, FACS Canto II, or FACS LSR II Fortessa flow 
cytometers (BD Bioscience) and data evaluated using Cell Quest Pro, FACS Diva (BD 
Bioscience) or FlowJo software (Tree Star). Purified antibodies or antibodies directly 
conjugated to biotin, FITC, PE, PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, Texas Red, APC, 
APC-Cy7, Alexa Fluor 700 or Pacific Blue were used. Streptavidin-FITC (eBioscience), 
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Streptavidin-PE (Jackson Lab), Streptavidin-PerCP-Cy5.5 (BD Bioscience) and Streptavidin-
APC (eBioscience) were used to detect biotin-conjugated antibodies. Purified antibodies were 
detected with a secondary goat anti-rat antibody conjugated to PE (Invitrogen). Routinely, 
staining with the respective isotype (armenian hamster IgG, rat IgG2a, rat IgG2b, or 
streptavidin without primary antibody) and fluorochrome was used as control to monitor 
unspecific background staining. 
 
2.2.9.1 Table of Directly Labeled Antibodies for FACS Analysis 
Name Alternative name Clone Company 
B220 CD45R RA3-6B2 BD, Abcam 
CD11b Mac-1 M1/70 BD, eBioscience 
CD11c Integrin-αx N418 or HL3 BD, eBioscience 
CD80 B7.BB1 16-10A1 BD 
CD86 B7.BB2 GL1 BD, eBioscience 
MHC II I-A/I-E 2G9 BD 
CD3 CD3 145-2C11 BD 
CD4 Ly-4 RM4-5 BD 
CD8α Ly-2 53-6.7 BD 
F4/80 F4/80 BM8 BioLegend 
PDCA-1 CD317 eBio927 eBioscience 
Mac-3 CD107b M3/84 eBioscience 
 
2.2.9.2 Table of Antibodies and Secondary Reagents for Indirect FACS Stainings 
Name Specificity Fluorochrome Company 
Biotin CD80 Biotinylated, murine CD80 - BD 
Biotin CD86 Biotinylated, murine CD86 - BD 
Biotin CD11b Biotinylated, murine CD11b - eBioscience 
Biotin CD11c Biotinylated, murine CD11c - eBioscience 
Streptavidin FITC Streptavidin conjugated FITC eBioscience 
Streptavidin PE Streptavidin conjugated PE eBioscience 
Streptavidin PE-Cy7 Streptavidin conjugated PE-Cy7 eBioscience 
Streptavidin APC Streptavidin conjugated APC Invitrogen 
Streptavidin eFluor 450 Streptavidin conjugated eFluor 450 eBioscience 
 
2.2.10 In Vitro Migration Assays 
Transwell migration assays were performed essentially as previously described
[101]
. To 
analyze migration of DC towards a chemokine gradient after MNP exposure, 2x10
5
 cells, 
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which had been treated with MNPs or activated using LPS overnight, were seeded in the 
upper compartment of Transwell migration plate and CCL19/ELC or CXCL12/SDF-1 
chemokines (100 ng/ml, Peprotech) were added to the lower compartment. Transmigration of 
DCs through Transwell inserts was analyzed after 90 min. In order to relate measured volume 
to cells counted in subsequent flow cytometric experiments, 1x10
4
 Dynabeads (equal 
concentration in all samples) were added to each sample retained from the lower chamber 
before analysis. Cells and beads were recovered and analyzed using flow cytometry by 
recording a fixed number of Dynabeads within each sample along migrated cells. 
 
2.2.11 Enzyme-linked Immunosorbent Assay (ELISA) 
Cytokine levels of frozen supernatant samples were analyzed according to the manufacturer’s 
protocols (R&D Systems, Duoset® and Quantikine®). Release of pro-inflammatory 
molecules IL-6, IL-12p40, and TNFα as well as the functional IL-1ß were investigated. For 
this purpose, 96-well plates were either coated using an appropriate capture antibody 
(Duoset® probes) or samples were directly added into wells of a pre-coated plate 
(Quantikine® probes). In order to remove unbound antibodies or otherwise interfering 
molecules, wells were thoroughly washed using buffer solution (PBS + 2% Triton X-100) 
after each reaction step. After protein binding and secondary detection antibody reaction, a 
1:1 mixture of H2O2 and tetramethylbenzidine was added. The resulting color shift due to 
bound HRP enzyme was measured quantitatively using a commercial plate reader (Molecular 
Devices) at 450 nm. The unknown protein concentration within supernatant samples was 
calculated in relation to the absorbance of known concentrations of recombinant protein 
standards. 
 
Table of ELISA Capture Antibodies: 
Detection 
antibody 
Specificity Origin Probe Set 
IL-6 goat anti-mouse 
biotinylated 
R&D Systems Duoset 
IL-12p40 goat anti-mouse 
biotinylated 
R&D Systems Duoset 
TNFα goat anti-mouse 
biotinylated 
R&D Systems Duoset 
IL-1ß anti-mouse enzyme 
conjugated 
R&D Systems Quantikine 
 
 
M a t e r i a l s  a n d  M e t h o d s | 39 
 
2.2.12 Ex Vivo Splenocyte Stimulation 
Explanted splenocytes were labeled with 5 µM carboyfluoresceine diacetate succinimidyl 
ester (CFSE, Molecular Probes) for 10 min at RT in the dark according to manufacturer’s 
guidelines (CellTrace
TM
, Molecular Probes) under continuous stirring. Subsequent quenching 
using FCS ensured equal labeling efficiency and increased viability of target cells. CFSE-
labeled splenocytes were seeded out at a concentration of 1x10
6
 cells/ml prior to MNP or 
control stimulation for 72 h in basic DC medium. Cells were kept in a cell culture incubator at 
37°C, 5% CO2 in the dark until further experimental procedures. After incubation, cells were 
prepared for counting and FACS analysis as outlined in 2.2.9. 
 
2.2.13 Magnetic Resonance Imaging 
2.2.13.1 Phantom Preparation and Immobilization of Cells 
100 mm and 35 mm cell culture plates (Nunc) were used in MRI studies. For the purpose of in 
vitro phantom preparation, plates were filled with 2% agarose (Invitrogen) and allowed to 
solidify. Using a commercial drill (Proxxon) fitted with a stand to control drilling depth and 
speed, boreholes with a diameter of 3.5 mm were drilled (depth 5 mm). Residual agarose was 
carefully removed to avoid the formation of air inclusions in later immobilization steps. 
Dilution series of magnetically pre-selected labeled cells were prepared, including final 
phantom concentrations of 10
5
, 10
4
, 10
3
, 10
2
 cells/ml and unlabeled control populations. 
Appropriate cell numbers were re-suspended in 20 µl PBS and mixed with an equal volume of 
low-melting agarose (Lonza) at RT and carefully pipetted into defined bore holes. After 
solidification, holes were sealed again using 2% agarose and phantoms were stored at 4°C 
until final MR measurements. 
 
2.2.13.2 MRI Scan Parameters 
MR images of agarose phantoms were acquired using a Bruker Biospec 11.7 T experimental, 
horizontal bore MRI scanner (Bruker Biospin) equipped with actively shielded gradient coils 
(16 cm diameter, 750 mT/m). A purpose built transmit-receive coil (4 cm diameter) was used 
for image acquisition. T2 relaxation times were determined using two-dimensional multi-slice 
multi-echo sequences (echo spacing = 11 ms, TE = 11-176 ms, TR = 5000 ms). Relative 
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signal intensities were determined using T2*-weighted 3D gradient echo FLASH sequences 
(TE = 15 ms; TR = 200 ms; flip angle 30°; Field-of-view 3.8 x 3.8 x 0.65 cm; isotropic 
resolution 74 m). 
 
2.2.13.3 MRI Data Analysis 
MR images were processed using the Bruker software ParaVision 4.0. Numerical map scan 
data was fitted using the following ParaVision software algorithm: T2 relaxation = A + C * 
exp (-t / T2), with A representing the absolute bias, and C referring to the signal intensity. 
Additional image analyses and numerical calculations needed to acquire i.e. contrast-to-noise 
ratio (CNR) were performed using NIH ImageJ.  
 
2.2.14 Statistical Analysis 
Statistical analysis of numerical data was performed using two-tailed and unpaired Studentʼs t 
test with GraphPad Prism 5.0 software (GraphPad Software Inc.). P-values below 0.05 were 
considered to be significant. 
 
2.2.15 Software Employed 
Microsoft Office software was employed in combination with most initial data acquisition 
hardware used throughout this study. GraphPad Prism 5.0 was used for primary data entries, 
subsequent statistical calculations, and basic figure layouts. The vector-based software 
CorelDraw was employed to finalize and adapt figures for best visual presentation and clarity. 
Adobe Photoshop and CorelPaint used for picture adaptation and noise-cancelations. In order 
to acquire raw numerical data sets from grey-scale and pseudo-color images, NIH ImageJ 
software and appropriate plugins were employed. 
Hardware-based software solutions were used accordingly and are outlined in the respective 
experimental section above. 
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3 Results 
 
3.1 Synthesis and Characterization of MNPs 
Magnetic nanoparticles on the basis of iron-oxide have long been recognized as vectors for 
biomedical applications such as MRI
[23,174]
. They provide superior T2 and T2* contrast 
enhancement and thus contribute to an enhanced clinical diagnosis and therapeutic treatment 
outcome. However, even though many iron oxide contrast agents are already approved for 
their use in clinical diagnosis, the mechanisms of interaction with and subsequent uptake into 
biological entities such as cells still remain elusive today
[7]
. 
To investigate these and other crucial parameters vital for therapeutic, diagnostic and research 
applications to come, MNPs displaying various surface properties such as charge, chemistry, 
as well as overall particle size were synthesized. Surface properties of engineered MNPs were 
custom-manufactured to yield a wide range of parameters to be investigated in conjunction 
with hematopoietic cells of various nature, developmental stages and origin. Shell 
components of MNPs not only stabilize magnetic cores and therefore provide 
biocompatibility, but also shape the interaction, subsequent uptake processes and resulting 
imaging characteristics within biological targets. It has been demonstrated in numerous 
studies that these chemical properties impact on interactions with biological 
systems
[154,175,176]
. 
Layer-by-Layer technology (LbL) was adopted to endow MNPs with a charged surface to 
enhance cell membrane interactions or invoke repulsive forces. The underlying principle of 
this novel technology is based on the coating of charged substrates onto an already existing 
layer of opposingly charged surfactant, thereby altering both the chemical surface properties 
as well as the overall diameter of particles
[162,177,178]
. 
Both positively charged poly-electrolytes such as poly-diallyl-dimethyl-ammonium-chloride 
(PDAD) and poly-ethylene-imine (PEI) and negatively charged poly-styrene sulfonate (PSS) 
were employed. PDAD represents an organic polymer that is being industrially used to 
reversibly bind and immobilize anionic substances
[179]
. Similarly, positively charged PEI is 
being employed to trap anionic colloids and macromolecules such as DNA, especially within 
acidic and neutral pH ranges
[180]
. In biological applications, both compounds are being 
deployed as cellular adhesion and transfection agents. On the other hand, the negatively 
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charged polymer PSS is frequently adopted in the context of ion exchange systems crucial for 
distinct industrial purposes
[181]
. 
In order to demonstrate practicability and ease-of-use of this novel technology platform, poly-
saccharides such as chitosan and dextran were included in this study. Both substrates are often 
used in clinical studies because of their inherent biological features as coating materials of 
MNPs
[182,183]
. 
Lipid-shell MNPs are already used in clinical practice and represent promising agents for 
drug delivery systems, and hence, oleate-stabilized MNPs were synthesized as control 
particles
[184]
. They are comprised of an iron core structure that is entrapped within a fluid lipid 
bilayer membrane consisting of oleate which confers both stability and biocompatibility
[185]
. 
The third group of nanoparticles is represented by molecules covalently bound to MNP 
anchor moieties such as PEG and Biotin. To investigate the impact on surface decoration 
density, various concentrations of coatings were synthesized and their impact recorded. Both 
substrates are known to avoid protein adhesion, and thus, reduce particle uptake by cells and 
evade systemic clearance mechanisms
[186,187]
. 
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Furthermore, biogenic magnetosomes of bacterial origin were included to investigate their 
potential to induce immunological responses within target immune cells. These magnetic 
nanoparticles are synthesized within certain bacterial strains in a process called biogenesis. 
Respective bacteria are endowed with the ability to orientate themselves with respect to the 
earth’s magnetic field in a process termed magnetotaxis. Substrates and synthesis 
modifications used to coat iron-oxide core particles are listed in Table 3.1. 
Chemical properties of MNPs such as their hydrodynamic diameter and zeta potential are 
important regarding cellular interactions, in particular uptake and shuttling routes employed 
by cells. Therefore, the analysis of distinct chemical parameters ensured particle homogeneity 
prior to the engagement of further experimental procedures (Table 3.2). In addition, both 
dynamic light scattering and zeta sizing technologies allow the investigation of particle 
stability and mono-dispersity following particle synthesis
[188,189]
. 
Covalently linked MNPs (Biotin, PEG) exhibited a neutral charge and very small overall 
diameter when compared to other MNP formulations employed in this study. All covalently 
linked MNPs showed a narrow size-range between 25-45 nm. In contrast, poly-electrolyte-
coated MNPs varied with respect to both their size and net surface charge. PDAD displayed 
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an average hydrodynamic diameter of 230 nm, yielding the largest poly-electrolyte MNP. As 
intended, PEI and PDAD showed very high positive zeta potentials of +50 ζ/mV, endowing 
particles with a strong positively charged interaction surface. On the other hand, PSS proved 
to be highly negatively charged (-53 ζ/mV) in zeta potential measurements. 
As outlined in Table 3.2, chemical parameters of Chit-MNP and Dex-MNP could not be 
determined successfully. During dynamic light scattering measurements, both MNPs resulted 
in multiple species ranging in size and net charge, thus prohibiting discrete and reproducible 
experimental outcomes. This finding can most likely be attributed to incomplete synthesis or 
particle agglomeration effects in aqueous solution. 
In general, synthesized iron-oxide based MNPs provided reproducible and stable chemical 
properties, allowing the investigation of their interaction with specialized hematopoietic cells 
that ultimately shape uptake and immunological consequences. 
 
3.2 Poly-Electrolyte and Lipid-Shell MNPs 
3.2.1 Hematopoietic Progenitor Cells 
Hematopoietic stem cells and their immediate downstream precursors are already in clinical 
use due to their therapeutic potential and plasticity to differentiate into all cell types of the 
blood
[39]
. In particular, cell replacement therapies prove to be promising therapeutic 
modalities in the treatment of i.e. leukemia
[190,191]
. 
Hematopoietic differentiation represents a regulated, continuous, and multi-linear process in 
which HSCs give rise to cells of different lineages through progressively limiting 
developmental options and a successive decline in self-renewal potential
[192]
. In this study, a 
myeloid CD11b
+
Flt3
+
 committed hematopoietic bone marrow progenitor cell was propagated 
and maintained in vitro using defined growth factors and culturing conditions as previously 
described
[101]
. 
Unlike true bone marrow resident HSCs, this amplified precursor has lost its long-term stem 
cell properties. However, this culturing system of explanted bulk bone marrow cells results in 
a homogenous population of myeloid committed progenitor cells that prove to be lacking 
lymphoid lineage markers such as CD3ɛ, CD4, CD8α, CD14, B220, and Ter119[101]. On the 
other hand, molecular markers conferring myeloid lineage commitment such as CD11b and 
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Gr-1 (Ly6C/G) are being expressed. Therefore, this experimental platform allowed a thorough 
investigation of the impact of MNPs on a homogenous stem cell-like progenitor population 
amplified to large numbers. 
 
3.2.1.1 Cytotoxicity Studies 
Biocompatibility can be defined as the ability of a biomaterial to perform its desired function 
with respect to a medical therapy, without eliciting any undesirable local or systemic effects 
within the recipient. The generation of the most appropriate beneficial cellular or tissue 
response, as well as the optimization of the clinically relevant performance of that therapy are 
thus not compromised
[193,194]
. 
Biological systems exposed to nanomaterials such as synthetic contrast agents potentially 
suffer from side effects elicited by components either integrated or released over time by such 
materials. Biodegradable macromolecules and polymers potentially trigger apoptosis, growth 
arrest, formation of reactive oxygen species (ROS) and similar adverse effects due to their 
presence
[154,195]
. Therefore, it remains crucial to exclude cytotoxicity within target cells by 
studying the degree of MNP biocompatibility prior to further experimental procedures. 
For this reason, both the effect of long-term MNP-treatment of HSCs for up to 72 h on their 
proliferative capacity as well as possible adverse effects arising from increased contrast agent 
concentration of up to 200 µg/ml were tested. As outlined in Figure 3.1A, HSC cell counts 
resembling the proliferative capacity after 72 h of continuous incubation with MNP 
formulations did not lead to decreased population numbers when comparing different MNP 
formulations. 
In addition, increased iron load did not yield significantly elevated rates of cell death as 
measured through a colorimetric MTT assay, thus proving a high degree of biocompatibility 
of all MNPs employed. Only Chit-MNP showed decreased numbers of surviving HSCs at 
very high labeling concentrations (200 µg/ml) when compared to other MNPs. However, 200 
µg/ml is far beyond the standard labeling concentration of 10 µg/ml for these experimental 
procedures, and thus, a reduction in cell viability is to be expected and within tolerable 
parameters (Figure 3.1B)
[196]
. 
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3.2.1.2 Uptake and Intracellular Iron Concentration 
Due to their inherent localization and function within a biological system, HSCs and their 
immediate downstream progenitors are not phagocytic in nature. However, MR contrast 
agents need to accumulate within target cells to confer imaging potential. In order to test 
uptake properties of MNPs into HSCs after 24 h of incubation, both efficiency and magnitude 
of iron oxide particles taken up by cells were investigated. MNP labeled HSCs acquire 
magnetic properties after MNP integration, and thus, can be separated using an external 
magnetic field. 
As illustrated in Figure 3.2A, only a fraction of cells adopted magnetic properties due to 
successful poly-electrolyte MNP integration. Notably, positively charged MNPs such as PEI 
and PDAD were taken up to a higher extent then negatively charged poly-electrolytes (PSS) 
and poly-saccharides (Chit-MNP, Dex-MNP). Poly-saccharide MNPs were taken up the least, 
with Chit-MNP and Dex-MNP yielding only 8 and 13% of labeling efficiency, respectively. 
Intracellular iron content within endosomal vesicles is crucial for MR imaging properties. To 
investigate uptake quantity of contrast agents, a colorimetric assay on the basis of FerroZine 
was utilized (Figure 3.2B). This organic salt forms a stable compound with Fe
2+ 
of 
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magnetically separated HSC lysates, and therefore, allows the quantification of the average 
amount of iron taken up by target cells
[173]
. 
Quantitative measurements of previously selected cells showed an average iron incorporation 
of up to 5-10 pg/cell. Values depicted in Figure 3.2B were normalized against unlabeled 
controls. Only Chit-MNP showed slightly lower uptake quantities, however, all values are in 
good agreement with similar studies previously conducted
[10,197]
. In summary, all poly-
electrolyte and lipid-shell MNPs employed were successfully taken up by HSCs, although to a 
lower magnitude when compared to their terminally differentiated effector cells. 
 
3.2.1.3 Intracellular Iron Stainings 
To visualize iron deposition within HSCs, Prussian blue staining was performed. This 
histological staining procedure is frequently employed to detect iron residues within i.e. 
biopsy specimens. During the course of staining, an acid solution of potassium ferrocyanide 
combines with  ferric iron (Fe
3+
) present in biological samples and results in the formation of 
a bright blue pigment called Prussian blue. This patho-histological staining technique allows 
the visualization of single iron granules within cells and represents one of the most sensitive 
detection assays for iron. 
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As illustrated in Figure 3.3, all particles proved to be localized within cytosolic structures 
inside HSCs. No adherence was noted on the outer membrane and within nucleic regions, 
confining iron deposition to the cytosol. 
However, larger aggregates were formed in case of Chit-MNP, most likely due to 
agglomeration effects prior to cellular uptake. Due to their size and overall inhomogeneous 
three-dimensional structure, these agglomerates were not taken up into cells successfully. 
Dark field microscopic inlets in Figure 3.3 show good localization of particles to confined 
areas and prove intracellular storage of MNPs within endosomal vesicles. 
 
3.2.1.4 Phenotypic Surface Marker Composition of Labeled HSCs 
Hematopoietic cells of various developmental stages cannot easily be discriminated from each 
other using conventional microscopic techniques. To assure that only target populations are 
being examined, surface marker stainings employing cytometry were performed. Distinct cell 
types display a specific repertoire of surface antigens that allow a conclusion as to their (i) 
developmental origin and lineage commitment, (ii) their current maturation state, as well as 
their (iii) viability state potentially being compromised due to MNP labeling procedures. 
To analyze possible phenotypic alterations of labeled HSCs due to MNP incorporation, levels 
of CD11b, CD11c, CD24 and Flt3 were examined (Figure 3.4A). CD11b represents an 
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integrin present on myeloid committed precursors, monocytes and differentiated innate 
immune cells
[198]
. CD11c is a hallmark protein of differentiated DCs and was used as a 
negative control in cytometric experiments of HSCs
[91]
. CD24, a glycosyl-
phosphatidylinositol-anchored protein, is expressed on immature cells of most, if not all, 
major hematopoietic lineages
[199]
. Flt3 represents a cytokine receptor expressed on the surface 
of hematopoietic progenitor cells
[103]
. Representative surface marker expressions are 
displayed in Figure 3.4A. 
As expected, expression levels for CD11b and CD24 were found to be very high and provided 
information about the lineage commitment and the undifferentiated phenotypic state of 
propagated HSCs, respectively. No alterations regarding status of differentiation were 
observed after MNP labeling procedures. Faint surface protein levels of CD11c did not 
exceed 9% of total gated cells, and thus, were considered neglectable. Furthermore, the 
increase in fluorescence intensity (FI) was considered neglectable, since only a minor 
intensity shift resulted after staining procedures when compared to isotype background 
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staining controls. Levels of Flt3 were elevated, undermining the undifferentiated nature of 
progenitor cell populations even after MNP-pulsing. 
As outlined in Figure 3.4B, none of the MNP formulations employed changed the surface 
marker makeup of the cells significantly when compared to unlabeled control stainings. This 
proved that successful uptake of particles does not result in change of cellular phenotype as 
would be the case during differentiation, cellular activation, or even apoptosis. 
 
3.2.1.5 In Vitro MRI Studies employing HSCs: Detection Limits 
Iron-oxide based MNPs are known to alter T2 and T2* MRI characteristics that enhances 
imaging of labeled cell populations when compared to their unlabeled counterparts. Reduction 
of signal intensity through shortening of relaxation times increases image contrast drastically. 
To test employed MNP formulations with regard to their potential as MRI contrast agents, in 
vitro phantom studies were performed. Cellular distribution within agarose phantoms proved 
to be very homogenous and uniform, allowing a quantitative comparison of different MNPs. 
Since iron oxide particles induce hypo-intense regions due to their potential of generating 
local magnetic field inhomogeneities, areas of contrast agent accumulation within cells show 
pronounced signal loss. To compare T2* signal reduction patterns and resulting 
maximum/minimum detection limits between contrast agents employed, 3D image stacks 
were mounted and results are displayed in Figure 3.5. 
All particles employed could be tracked down to a concentration of 10
3
 cells. However, Chit-
MNP proved to be the least effective contrast agent that was only traceable down to the 
lowest cell seeding density of 10
4
 cells. The maximum seeding density that still provided 
decent contrast between individual signal reduction areas proved to be 10
5
 seeded HSCs in 
case of OLS and Dex-MNP. Most likely, other MNPs would have required a higher seeding 
density to achieve similar T2 signal reduction patterns. 
In summary, all particles used in this study were effectively imaged within HSCs after 
cellular incorporation using T2* weighted MR scans. However, especially PEI-MNP proved 
to be superior when compared to other poly-electrolyte and OLS-MNP imaging agents 
employed. 
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3.2.1.6 In Vitro MRI Studies employing HSCs: Relaxivity 
In molecular imaging, relaxivity provides valuable information about the contrast of target 
structures compared to their unlabeled adjacent environment
[200]
. To provide numerical data 
of the respective MNPs using MRI, map scans were performed and resulting T2* signal 
reduction patterns were plotted against pre-defined but varying echo times. 
As outlined in Figure 3.6, signal intensities of aqueous MNP solutions (Figure 3.6A) (iron 
conc. 10 µg/ml) were substantially lower when compared to values obtained after 
incorporation of MNPs into viable HSCs (Figure 3.6B). In particular, PSS and OLS-MNP 
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represented strong contrast agents inside HSCs due to their capacity to decrease T2* signal 
intensity at very low echo times (5-15 ms) when compared to control levels. Since 
surrounding tissues do not provide such a strong negative impact on MRI signal, contrast can 
be expected to be enhanced markedly. On the other hand, the polysaccharide-coated MNPs 
and PDAD-MNP did not appear to lower signal intensity to such a high degree, making them 
less efficient at imaging lower numbers of HSCs. In summary, however, all of the employed 
MNPs proved to be suitable intracellular HSC contrast agents in MR imaging. 
After fitting raw map scan data to numerical values, T2 relaxation times of each individual 
MNP were obtained. Table 3.3 provides information about the capacity of synthesized 
nanoparticles to serve as MRI contrast agents. Individual data points of curves shown in 
Figure 3.6 were fitted using both ParaVision and ImageJ software to allow the calculation of 
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T2 relaxation times under the given experimental conditions. As previously demonstrated, 
PSS and OLS-MNP showed T2* relaxation times below 40 ms, and thus, represent the most 
efficient contrast agents for tracking HSC in this study. On the other hand, Chit-MNP 
provided high T2* relaxation times in both aqueous solution and within target cells, making it 
less efficient at detecting embedded target cells. 
 
3.2.2 Inflammatory Dendritic Cells (iDCs) 
Propagated myeloid committed precursors can be differentiated into inflammatory DC-like 
cells of the myeloid lineage using GM-CSF
[101]
. Under continuous administration of GM-CSF 
growth factor, cells undergo consecutive differentiation steps until acquiring an immature DC 
phenotype. In particular, inflammatory DCs are believed to arise as a consequence of 
circulating monocyte stimulation and subsequent differentiation similar to macrophages
[41]
. 
Due to the prior amplification of myeloid committed progenitor cells, iDCs, macrophages and 
granulocytes all arise throughout the remainder of the culture. Since DCs represent the bridge 
between innate and adaptive immunity due to their pivotal role in the induction of adaptive 
immune responses, they were included in this study to investigate the immunological 
consequences of MNPs employed. DCs represent highly phagocytic cells in their immature 
state prior to their activation, making them a particularly attractive target cell type to 
investigate MNP uptake and imaging properties in both research and clinical applications
[13]
. 
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3.2.2.1 Biocompatibility Studies 
Biocompatibility studies utilizing immature inflammatory DCs were performed using both 
MTT colorimetric assays as well as cytometry employing 7-aminoactinomycin (7-AAD). 
MTT assays only allowed the analysis of bulk cultures that were stimulated with respective 
MNP formulations for 24 h, whereas 7-AAD staining permitted a cytotoxic screening of 
magnetically pre-selected as well as cytometrically gated iDC populations. 7-AAD resembles 
an organic peptide that intercalates into DNA of dead or dying cells after crossing the 
disrupted cellular membrane
[201]
. Using flow cytometry, it is possible to detect the 7-AAD 
fluorescence signal inside individual cells that allows a monitoring of dye incorporation. 
As outlined in Figure 3.7A, all MNPs provided superior biocompatibility even when 
subjected to high contrast agent concentrations (200 µg/ml). As previously discussed, Chit-
MNP showed slightly elevated levels of cytotoxicity when compared to other MNP 
formulations employed. Figure 3.7B graphically illustrates the gating strategy of data 
presented in Figure 3.7C. 
Biocompatibility in general is decreased after increasing MNP labeling concentration and 
results obtained further substantiate data gathered in Figure 3.7A. OLS-MNP and PDAD-
MNP represented the most biocompatible MNP formulations with only about 15% of iDCs 
displaying adverse cellular effects at the highest labeling concentration of 200 µg/ml. Within 
commonly used labeling concentration ranges used in literature
[202]
, however, all particles 
proved to be highly biocompatible. 
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3.2.2.2 Uptake and Intracellular Iron Concentration 
Magnetic separation techniques were utilized to part the unlabeled cell fraction from their 
labeled counterparts. This allowed a qualitative estimation of the degree of uptake as well as a 
quantification of iron deposition. 
In contrast to HSCs, iDCs readily take up all MNP formulations to a high degree (Figure 
3.8A). Chit-MNP resembled the only exception, as it was only successfully integrated by 40% 
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of total cells. Charged MNPs and OLS-MNP were taken up to the highest extent, with more 
than 75% of total iDCs being labeled after 24 h of incubation. 
Magnetically separated iDCs were subjected to FerroZine iron assay to determine intracellular 
iron load. As shown in Figure 3.8B, labeled iDCs acquired a high amount of iron on average 
per cell. Charged poly-electrolyte particles were taken up to a very high extent, ranging from 
45-80 pg/cell. Although in the case of OLS-MNP only 48 pg/cell of iron was acquired by 
cells, in summary all particles employed displayed good uptake characteristics in DCs. 
 
3.2.2.3 Histological Staining of MNP-Labeled iDCs 
To visualize intracellular localization and possible clustering of MNPs employed, histological 
iron staining of cytospins were performed. In this staining procedure, the synthetic compound 
Prussian blue is used to detect the presence of iron in biological specimens. 
As shown in Figure 3.9, all iron residues originating from iron deposits within endosomal 
structures could be visualized. It is worth noting that all MNPs were localized confined to the 
cytoplasm. No staining patterns were observed within the nucleus or loosely attached to the 
outer membrane, providing initial evidence as to complete uptake processes. However, Chit-
MNP displayed clustering of particles, as staining pattern obtained differ from ones seen with 
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other MNP formulations. Furthermore, the magnitude of iron staining pattern were decreased 
in the case of PEI-MNP compared to other particles tested. 
Overall, particles were successfully imaged using Prussian blue histological staining of fixed 
cytospins. Areas of intense staining patterns appeared to be confined to the cytosol, most 
likely within endosomal vesicles. 
 
3.2.2.4 Transmission Electron Microscopy (TEM) and Endosomal Packaging 
To further substantiate findings related to intracellular fate and packaging properties of 
MNPs, transmission electron microscopy (TEM) analyses were performed. TEM provides 
information about the electron density of a given biological specimen that relies on the 
electron beam stopping power of imaged structures. 
Figure 3.10A displays low-resolution pictures of inflammatory DCs labeled with respective 
particles. MNP depositions are marked with white arrows to improve visualization. As can be 
observed, clustering patterns varied with respect to the different surface chemistries of the 
nanoparticle at hand. Magnified images of specific endosomal structures containing iron 
oxide residues substantiate this observation even further. 
As seen in Figure 3.10B, PEI, PSS, Dex and Chit-MNP tended to be packaged more loosely 
when compared to PDAD and OLS-MNP. To further investigate this finding, regions of 
interest (ROIs) marked in white were normalized against surrounding background and 
greyscale values were deduced. Figure 3.10C shows numerical evaluation of electron density 
as derived from greyscale values. Strikingly, PDAD and OLS-MNPs showed a significantly 
58 | R e s u l t s  
 
higher electron density than other MNP formulations employed. As can be visually confirmed 
from Figure 3.10B, PEI-MNP, PSS-MNP, Chit-MNP, and Dex-MNP displayed lower 
normalized electron densities in numerical evaluation of greyscale values (Figure 3.10C). 
In summary, TEM measurements provided valuable information as to the intracellular 
localization and fate of engulfed particle formulations within iDCs. Furthermore, high-
resolution images of specimen slices allowed the deduction of particle packaging properties 
and density on the basis of their electron attenuation. 
 
3.2.2.5 Phenotypic Surface Marker Composition 
DC subsets are known for their abundance of surface markers related to both innate and 
adaptive immunity
[100]
. These proteins indicate the real-time maturation status of individual 
cells and therefore allow a monitoring of potential changes after a given stimulus. To test 
whether or not MNPs induce immunological consequences within these cells, flow cytometric 
analyses were employed. 
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CD11c and MHC II both represent proteins expressed on the surface of professional antigen-
presenting cells such as iDCs. Even though CD11c levels remain constant after terminal 
differentiation, MHC II levels are subject to change depending on the maturation state of the 
cell
[203]
. Upon activation via a foreign stimulus, elevated levels of MHC II are being recorded. 
In conjunction with CD80 and CD86, both members of the B7 co-stimulatory molecule 
family, conclusions on the activation state of iDCs can be drawn
[204]
. Whereas immune cells 
only express low levels of these two surface proteins critically involved in the functional 
stimulation of naïve T-lymphocytes in secondary lymphoid organs, activated APCs rapidly 
increase their abundance. 
As shown in the top row of Figure 3.11 (unlabeled control, black histogram), surface 
expression levels of MHC II, CD80 and CD86 proved to be fairly low in unstimulated iDCs. 
In contrast, these values were vastly up-regulated (red histogram) upon cellular activation 
using LPS. 
However, unlike LPS stimulation, none of the employed MNPs caused up-regulation of 
surface proteins relevant for activation and antigen presentation. Therefore, MNP 
formulations are biologically inert and do not trigger potential immunological consequences 
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within iDCs. Surface marker profiles remain subject to minor variations based on the in vitro 
culturing conditions. However, fluctuations remained within acceptable ranges. 
Samples shown in Figure 3.11 were magnetically pre-selected, denoting that target cells did 
successfully acquire MNPs prior to cytometric analysis. On the other hand, unlabeled 
counterpart fractions did also not show up-regulation of MHC II, CD80 and CD86, however, 
they displayed a more mature phenotype (data not shown). This finding is in agreement with 
current knowledge on DC biology implying that only immature iDCs retain the capability of 
enhanced phagocytosis
[205]
. 
 
3.2.2.6 In Vitro Migration Assay 
Cellular activation triggers DCs to up-regulate the expression of migration-dependent 
genes
[204]
. Using iDCs, an in vitro migration assay was employed to investigate the potential 
of MNP-stimulated DCs to acquire a migratory phenotype. After being activated through the 
uptake and processing of an external antigen, DCs migrate towards draining lymph nodes in 
order to present the acquired antigenic information to naïve T cells, and thus, initiate an 
appropriate adaptive immune response
[104]
. 
MyD88
-/-
 knockout iDCs were included in the study to test whether MNPs possibly signal 
through TLR4 in a MyD88 adaptor protein dependent manner. As outlined in Figure 3.12, 
poly-electrolyte and OLS-MNPs did not show a significant up-regulation of their migratory 
behavior when compared to untreated controls. In addition, no significant difference between 
cell numbers of Wt and MyD88 knockout cells were observed, proving the lack of TLR 
involvement with respect to the nanoparticles tested. 
However, LPS is known to signal exclusively through the TLR4 receptor, and therefore, 
MyD88
-/-
 knockout iDCs served as control of cell functionality. As shown in Figure 3.12, 
numbers of migratory LPS-treated cells significantly dropped in case of cells devoid of the 
adaptor protein MyD88 relevant for TLR signaling and subsequent NFκB gene activation. 
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3.2.2.7 In Vitro MRI Studies and Relaxivity 
To further investigate MRI properties of MNP formulations employed in iDCs, MRI 
relaxometry studies were performed. Image contrast represents an important asset of MR 
imaging that enhances both imaging quality and differentiability
[206]
. In particular, contrast-to-
noise ratio allows a quantifiable rating of contrast agent performance according to their 
capability to induce local field inhomogeneities. 
As outlined in Figure 3.13, T2 map scans revealed good signal reduction patterns of MNPs. 
Figure 3.13A depicts pseudo-color images of labeled iDCs within in vitro phantom drillings. 
As outlined by the color legend, all particles except Chit-MNP and PSS-MNP showed low T2 
relaxation times for all seeding densities examined. However, especially Chit-MNP and PSS-
MNP proved to be inferior when compared to contrast agent characteristics of other employed 
poly-electrolyte and lipid-shell MNPs. 
Figure 3.13B depicts the degree of linearity of R2 relaxation rates with regard to seeding 
density. Only Chit-MNP and PSS-MNP proved to be less efficient when compared to the 
remaining MNP formulations employed, resulting in a marked drop of R2 at lower seeding 
densities. Therefore, the linear relationship between R2 and seeding density was 
compromised below 10
3
 cells seeded. 
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In summary, relaxivity data of all MNPs showed linear relationship between seeding density 
and resulting R2 relaxation rates within a wide range of seeding densities, providing good MR 
capabilities of employed MNPs within labeled iDCs. 
 
3.2.2.8 In vitro MRI Detection Limits and CNR Values 
To further investigate minimum and maximum possible detection limits within agarose 
phantoms, T2* image stacks were mounted. These values provide information about the 
contrast agent potential of employed MNPs even when imaging low numbers of target cells 
within a given area. Contrast to noise ratio is a measure to determine image quality of regions 
of interest (ROIs) in comparison to background “noise”. A high CNR ratio translates into 
good visualization and differentiability of structures, and thus, denotes excellent MR contrast 
agent properties. 
Figure 3.14A displays a cross-sectional view of an imaged agarose phantom and signal loss 
patterns observed to deduce minimum and maximum cut-off section numbers to be used in 
further analyses. OLS-MNP and PDAD-MNP displayed superior image contrast and cells 
could be successfully imaged down to a seeding density of only 10
2 
cells (Figure 3.14B+C) 
with relatively high CNR remaining. On the other hand, Chit-MNP CNR ratios declined 
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rapidly, even falling below background levels in case of low numbers of embedded target 
cells. Using this particular MNP, it was only possible to successfully image 10
4
 embedded 
cells. 
Contrast to noise ratio remained within good performance levels for all MNPs down to 10
3
 
embedded cells with Chit-MNP being the only exception. 
In conclusion, all synthetic MNPs are suitable contrast agents to visualize iDCs, however, 
PDAD and OLS-MNP displayed superior imaging characteristics and proved to be most 
suited for imaging low numbers of iDCs within a given target volume. 
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3.2.3 MNP stimulated Flt3L-Generated DC Subsets 
Flt3, a tyrosine kinase known to be crucially involved in lymphocyte development, stimulates 
differentiation towards the lymphoid lineage of blood cells, such as B-, T cells and DCs. This 
observation has led to the development of defined experimental procedures to differentiate 
bone marrow cells into various subsets of DCs. 
In this study, Flt3 ligand (Flt3L) was used to induce differentiation of murine bone marrow 
progenitors to yield both conventional (cDCs) as well as plasmacytoid dendritic cells (pDCs). 
Both cell types have important functions in steady-state and inflammation, and therefore were 
used as targets for MNP stimulation. 
 
3.2.3.1 MNP Stimulation of Flt3L Generated cDCs in the Context of Knockouts 
Since Flt3L induces the differentiation into both cDCs and pDCs to roughly equal amounts, it 
is crucial to exclude unwanted cell populations to obtain adequate experimental results. As 
illustrated in Figure 3.15, cDCs express high levels of both CD11b and CD11c. Due to this 
myeloid commitment and apparent DC phenotype, a CD11b
+
CD11c
+
 double-positive gate 
was used to exclude pDCs from further experimental analyses. As outlined in Figure 3.15, 
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cDC gates were selected to further analyze surface expression levels of both CD80 and CD86 
co-stimulatory molecules. The area of interest included cell fractions that were both CD80
high
 
as well as CD86
high
. Approximately 38% of total gated cells were positive in case of 
unstimulated controls, whereas LPS stimulation significantly increased this fraction up to 
77%. 
To further investigate possible uptake and signaling mechanisms of Flt3-generated cDC 
populations, TLR4 and TLR9 knockout cells were employed. These toll-like receptors are 
critically involved in the recognition of foreign structures of both bacterial and viral origin, 
and lead to the induction of primary immune responses
[92]
. As previously discussed, MyD88 
represents a signaling molecule downstream of the initial receptor-ligand recognition that is 
involved in translating the acquired surface information through signaling cascades of both 
receptors into nuclear expression of i.e. NFκB target genes[204]. The ASC protein is involved 
in the inflammasome pathway that recognizes both PAMPs and DAMPs through the cleavage 
of pro-caspase 1
[207]
. 
Figure 3.16 depicts the numerical evaluation of CD80
high
CD86
high
 gates as shown in Figure 
3.15. As previously reported in similar experiments, poly-electrolyte MNPs did not trigger 
significant up-regulation of assessed surface marker levels in Wt as well as TLR4
ko
, TLR9
ko
, 
MyD88
ko
, and ASC
ko
 cells. Levels of surface expression are subject to small variations but 
remained within expected fluctuation levels. Cellular maturation due to LPS treatment 
resulted in the up-regulation of relevant surface levels as well as proving cellular integrity. 
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Due to the involved recognition and signaling dependencies of LPS, cellular responses of 
cDCs was compromised in TLR4
ko
 and MyD88
ko
. 
In summary, both positively charged PDAD-MNPs and particles possessing negative surface 
functionalization (PSS-MNP) did not alter levels of co-stimulatory molecules present on 
Flt3L generated cDC populations. Cytometry data suggests biological inertness of MNP 
formulations unlike stimulation using LPS that triggered a pronounced up-regulation of 
maturation dependent surface markers, and thus, led to the activation of cDCs. 
 
3.2.3.2 MNP Stimulation of Flt3L Generated pDCs in the Context of Knockouts 
In addition to generating cDCs, driving bone marrow derived progenitor cells into 
differentiation using Flt3L generates pDCs
[161]
. These cells induce vast amount of IFNs upon 
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cellular maturation and are critically involved in fighting viral infections, especially in a 
TLR9 dependent manner
[208]
. 
Figure 3.17 graphically illustrates the gating strategy of Flt3L generated pDCs. Cells were 
pre-selected for further experimental procedures including CD11c
+
CD11b
-
PDCA-1
+
B220
+ 
fractions of total live cells as depicted in Figure 3.18. Levels of surface staining for MHC II 
and CD86 were evaluated and used for data acquisition and subsequent evaluation. 
Unstimulated control levels for both MHC II and CD86 gates were undetectable within 
selected gates. However, numerical values increased to 24% and 16% after cellular activation 
using LPS, respectively (Figure 3.17B, right column). 
Numerical data of MHC II
high
 and CD86
high
 gates are outlined in Figure 3.18. Even though 
pDCs did not yield surface marker abundance levels recorded for cDCs after LPS stimulation, 
a significant increase in surface marker levels was noted. Due to the fact that LPS is 
recognized by TLR4, surface marker expression dropped down significantly in case of TLR4 
knockout cells. 
However, both PDAD- and PSS-MNPs did not alter surface expression levels of neither 
CD86 nor MHC II beyond the control baseline significantly. Furthermore, employed TLR4 
and TLR9 knockout cells did not result in experimental differences regarding cytometric 
readouts, undermining the lack of PRR involvement in the recognition of poly-electrolyte 
MNPs employed in this study. 
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In summary, poly-electrolyte MNPs proved to be biologically inert and did not lead to an up-
regulation of maturation-dependent surface proteins in pDCs. 
 
3.2.3.3 ELISA Data of Bulk Supernatants after LbL-MNP Stimulation 
Immune cells release pro-inflammatory cytokines into their immediate surroundings after 
cellular activation events through NFκB signaling and enhanced protein expression. The 
repertoire of cytokines ultimately released strictly depends upon the nature of the initial 
stimulus. To further investigate cytokine release of DCs into their surroundings, ELISA 
experiments were performed. Detection of pro-inflammatory cytokines was used to 
undermine data acquired during cytometric experiments as well as providing evidence as to 
the type of cellular activation. 
Bulk cultures of Flt3L generated DCs were stimulated with poly-electrolyte MNPs for 24 h 
and supernatants were assessed as to their cytokine content. As depicted in Figure 3.19, 
neither PDAD-MNP nor PSS-MNP led to a pronounced release of IL-6, IL-12p40, and TNFα 
pro-inflammatory cytokines beyond unstimulated control levels in Wt bulk DCs. No evidence 
as to PRR involvement was found due to the absence of released cytokines. However, LPS 
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stimulation resulted in a significant elevated sequestration of immune-stimulatory proteins 
into the supernatant in a TLR4-dependent manner. 
On the other hand, none of the employed poly-electrolyte MNPs resulted in elevated levels of 
pro-inflammatory cytokines in the context of TLR4
ko
 and TLR9
ko
. Protein content did not 
exceed base-line levels recorded for untreated controls, and thus, further undermined the 
inertness of particle formulations employed. 
 
3.2.4 Poly-Electrolyte MNP Stimulation of Macrophages 
Macrophages are part of the RES system, and therefore, represent crucial entities in uptake 
and subsequent clearance of foreign matter, including synthetic MNPs
[209]
. Macrophages 
differentiate from monocytes that circulate the blood in steady state and extravasate upon 
terminal differentiation. In order for them to fulfill their role as scavengers in both steady-
state and inflammation, they possess a vast amount of surface receptors and intracellular 
proteins such as TLRs
[93]
. 
In vitro, they can be differentiated from bone marrow precursors with the aid of M-CSF. This 
growth factor is critically involved in the proliferation and maintenance of bone marrow 
progenitor cells and monocytes, while additionally leading to the differentiation into 
macrophages and DCs
[210]
. Although macrophages can be obtained through the usage of other 
growth factors to some extent, M-CSF stimulation leads to a homogenous population of 
adherent precursors and macrophages, and thus, represents a suitable in vitro modeling system 
to study the cellular impact of MNP exposure. 
 
3.2.4.1 M-CSF derived Macrophages: FACS Profiling and Gating Strategy 
To ensure that cell populations of interest display phenotypic hallmark surface proteins of 
murine macrophages, flow cytometric analyses were performed prior to further experimental 
procedures. Figure 3.20 outlines the gating strategy during cytometry measurements 
including live gating (Figure 3.20A) and CD11c
neg
CD11b
pos
F4/80
pos
 pre-gating to yield viable 
macrophage populations (Figure 3.20B). Phenotypic status markers used include CD86 and 
Mac-3, both of which are known to be up-regulated upon cellular activation. In un-stimulated 
macrophages, expression of CD86 was absent and similar to control isotype staining (light 
70 | R e s u l t s  
 
grey histogram, Figure 3.20B). On the other hand, Mac-3 was already expressed to some 
extent in un-stimulated immature macrophages on day seven of in vitro cultures. However, 
levels could be further increased following LPS stimulation as depicted in Figure 3.20. 
 
3.2.4.2 Macrophages: Phenotype in the Context of TLR4 Knockouts 
Cytometric surface profiling of CD86 and Mac-3 was performed after MNP stimulation of M-
CSF generated murine macrophages in both the context of Wt and TLR4 knockout cells. 
Figure 3.21 illustrates macrophage FACS profiles obtained after 24h of incubation with 
respective poly-electrolyte MNPs. 
LPS yielded a significant up-regulation of both CD86 and Mac-3 surface proteins when 
compared to unstimulated control levels. However, elevated presence of the respective 
molecules dropped down significantly in case of TLR4 receptor knockout cells. PDAD- and 
PSS-MNPs did not result in an increase in surface expression of neither Mac-3 nor CD86, 
again substantiating the inertness of particle formulations. 
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3.2.4.3 ELISA Cytokine Secretion in the Context of TLR4 Knockouts 
Macrophages are phagocytic cells of the innate immune system that sense potential harmful 
PAMPs and DAMPs within their immediate environment and react accordingly by recruiting 
additional immune cells through the release of pro-inflammatory cytokines
[74]
. Both TLR4 
and the adaptor molecule ASC are critically involved in the recognition and subsequently 
resulting immunological consequences after PAMP and/or DAMP exposure, and thus, 
relevant knockout systems were included in these studies. 
To test whether M-CSF generated murine macrophages sense poly-electrolyte MNP 
formulations as potentially harmful, ELISA measurements detecting released IL-6, IL-12p40, 
and TNFα in the context of TLR4 receptor knockout cells were performed. 
As shown in Figure 3.22, all particle suspensions were tolerated by macrophages and did not 
induce significant release of tested cytokines. As expected, treatment of murine macrophages 
with LPS resulted in a significant decrease of secreted cytokine levels in TLR4 knockout 
cells. ASC
ko
, however, displayed protein release similar to Wt macrophages. 
In summary, synthetic poly-electrolyte nanoparticle formulations proved to be biologically 
inert within murine macrophages independent of their size and surface makeup. 
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3.2.5 Mixed Splenocyte Responses after Poly-Electrolyte MNP Stimulation 
Secondary lymphoid organs such as lymph nodes are the primary site of adaptive immune 
responses
[81]
. Antigenic information acquired from peripheral tissues is brought into close 
proximity with both T- and B-lymphocytes that are capable of translating the peptide 
information presented to them through immigrating APCs. As a result, massive cell division 
and proliferation increases the potential number of clones being able to mount an immune 
reaction against a specific antigen
[46,91]
. In the case of T cells being activated through 
migratory or lymph node resident DCs, one of several effector phenotypes (Th1, Th2, Th17, 
Treg) is induced
[78,211]
. In the case of lymph-borne antigens such as MNPs, particles undergo 
immune surveillance in secondary draining lymph nodes, and thus, splenocyte cultures were 
employed to mimic ex vivo immunological detection of soluble antigens. 
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This process is highly dependent on the size and overall surface properties of administered 
iron oxide based contrast agents. In this case, lymph node resident immune cells are 
responsible for the identification, uptake and resulting lymphocyte priming
[212]
. 
 
3.2.5.1 T cell Proliferation Capacity after LbL-MNP Stimulation 
Mixed splenocytes were harvested from explanted spleen and prepared to yield a homogenous 
cell population through mechanical disintegration as well as enzymatic action. MNP 
stimulation was carried out for a period of 72 h and cell numbers were assessed. These served 
as an indication of overall cell division events taking place as a result of MNP exposure 
accumulating throughout the incubation time. 
As depicted in Figure 3.23, approximately 0.5x10
6
 cells remained after 72 h of incubation in 
case of unstimulated control samples. On the other hand, LPS stimulated controls resulted in a 
3-fold increase of total splenocytes, whereas CpG treated populations did not alter cell 
numbers when compared to negative controls. 
In summary, none of the poly-electrolyte MNPs tested proved to be able to induce cellular 
proliferation and division events under the experimental conditions. Total splenic cell 
populations after 72 h of incubation with PDAD- and PSS-MNP did not yield a significant 
increase in cell numbers when compared to unstimulated control samples. 
To further substantiate findings obtained with whole spleen cultures, explanted single cell 
suspensions were labeled using CFSE dye. The succinimidyl-group of this stain covalently 
binds to intracellular proteins, and thus, is retained within target cells. Upon cellular division 
events, the total amount of the dye is passed on to equal amounts to both daughter cells, 
allowing a quantitative estimation of cellular activity. Using flow cytometry, the fluorescence 
signal of each cell can be obtained and compared separately. To ensure correct gating 
strategy, CD45
+
CD3
+
 double positive cells were pre-gated to exclude B cells and other 
spleen-derived cell populations (Figure 3.23A). 
Figure 3.23C displays CFSE fluorescence intensities after 72 h of MNP exposure of both 
CD4
+
 and CD8
+
 T cell populations. Splenocytes were first explanted, mechanically and 
enzymatically resuspended, and subsequently labeled with CFSE. 
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Apart from LPS control stimulation, none of the poly-electrolyte MNPs employed was 
capable of inducing T cell proliferation within single cell suspensions of splenic explants. 
CFSE patterns showed a marked decrease of fluorescence in LPS treated total spleen 
populations when compared to the maximum signal of untreated splenocytes (FI~10
3
), 
providing evidence as to cellular division events of pre-gated T cells. 
Overall, CFSE labeling of total splenocyte populations revealed that potentially lymph born 
synthetic MNPs would not alter cell numbers of total T cell populations. Therefore, both 
PDAD and PSS particle functionalization were regarded biologically inert. 
 
3.3 Immunological Properties of Bacterial Magnetosomes 
Biogenic magnetosomes represent bacterial organelles organized into membranous chains of 
iron oxide cores
[213]
. The linear structure serves as a compass, allowing certain bacterial 
strains to orientate themselves in geomagnetic fields, a process termed magnetotaxis
[165]
. 
Magnetosome crystals possess high chemical purity, narrow size ranges, and species-specific 
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crystal morphologies. Unlike synthetic MNPs, magnetosomes are composed of large single 
domain iron cores that reach diameters of up to 30-45 nm. Interestingly, iron oxide structures 
displaying these properties cannot be successfully synthesized using modern state of the art 
chemistry. This fact makes them particularly interesting for molecular imaging approaches as 
well as possibly introducing immunological consequences due to their bacterial origin. 
 
3.3.1 Hematopoietic Progenitor Cells 
3.3.1.1 Biocompatibility Studies of Bacterial Magnetosomes using HSCs 
In order to investigate the potential of MSR-1 to induce adverse cytotoxic effects within 
HSCs, biocompatibility studies were performed. As illustrated in Figure 3.24, both 
concentration-dependent and long-term MNP exposure treatments were employed. Figure 
3.24A depicts percent survival of MNP-exposed HSCs with increasing magnetosome 
concentrations. Even though surviving cell numbers dropped when increasing MNP 
concentration up to 200 µg/ml, levels of remaining HSCs were comparable to other MNPs 
employed in similar studies (Figure 3.1A). As previously observed, a correlation between 
surviving HSCs and iron oxide labeling concentration showed a dose-dependent cytotoxic 
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effect of labeled HSCs. Furthermore, cellular amplification was not compromised after long-
term incubation with MSR-1 for 72 h. As illustrated in Figure 3.24B, cell numbers remained 
within acceptable levels when compared to Figure 3.1B. 
 
3.3.1.2 MSR-1 Uptake Studies employing HSCs 
Uptake studies of bacterial MSR-1 into proliferating HSCs were employed using a labeling 
concentration of 10 µg/ml. As illustrated in Figure 3.25, approximately 25% of total HSCs 
successfully incorporated biogenic MNPs. When compared to other MNP formulations 
employed in similar studies (refer to Figure 3.2), labeling with MSR-1 resulted in a high 
percentage of total HSCs acquiring magnetic properties due to MNP uptake. 
However, intracellular iron concentrations of magnetically pre-selected HSCs remained low. 
On average, only 6 pg of iron per cell was measured. Apart from Chit-MNP previously 
discussed, MSR-1 resulted in the lowest intracellular iron concentration when compared to 
poly-electrolyte coated MNPs (Figure 3.2B). 
Potential clustering effects of biogenic MNPs arising in aqueous solutions and intracellular 
localization were visualized employing Prussian blue stainings of fixed cytospins. As depicted 
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in Figure 3.25C, MSR-1 MNPs were successfully incorporated into HSCs. However, larger 
aggregates of particles appear to be adhering to the outer membrane of target cells. 
In summary, bacterial magnetosomes were taken up by a large amount of cells, although not 
to a high degree when compared to other MNP formulations. Histological stainings confirmed 
intracellular localization of particle agglomerates. 
 
3.3.1.3 Phenotypic Profiling of MSR-1 pulsed HSCs 
In order to investigate surface marker make-up of magnetosome pulsed HSCs, flow 
cytometric analyses were performed. Cells were labeled for 24 h and magnetically separated 
prior to experimental procedures. As illustrated in Figure 3.26, no significant differences in 
surface marker profiles were detected when comparing MSR-1 labeled HSCs with untreated 
control samples. The adopted gating strategy employed to yield numerical evaluation of data 
is outlined in Figure 3.4A. In summary, exposure of HSCs with bacterial MNPs did not 
induce any phenotypic alterations of CD11b, CD11c, CD24 and Flt3 that would suggest the 
induction of differentiation or potential adverse effects arising as a consequence of bacterial 
MSR-1 exposure. 
 
3.3.1.4 Molecular Imaging Properties Employing MSR-1 
In vitro phantom studies were employed to investigate MR imaging characteristics of 
bacterial magnetosomes. In brief, defined numbers of MSR-1 labeled HSCs were 
immobilized within agarose and subjected to MR imaging. As depicted in Figure 3.27, 
labeling of HSCs with bacterial MNPs resulted in a marked decrease of signal intensity when 
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compared to controls (Figure 3.27A + C). Bacterial magnetosomes could be imaged down to a 
minimum detection limit of 10
2
 cells, rendering them particularly attractive for the imaging of 
low numbers of target HSCs. When compared to similar studies employing poly-electrolyte 
and lipid-shell MNPs, MSR-1 MNPs displayed remarkable MR characteristics given these 
experimental settings. Due to their low T2* relaxation time values (32 ms ± 8 ms), 
magnetosomes proved to be a valuable contrast agent for imaging of HSCs using MRI. 
 
3.3.2 Inflammatory Dendritic Cells (iDCs) 
3.3.2.1 Uptake Properties of Bacterial Magnetosomes into Inflammatory DCs 
To investigate the uptake potential of MSR-1 MNPs into GM-CSF derived iDCs, cells were 
labeled for 24 h and magnetically separated as previously discussed. As outlined in Figure 
3.28A, MSR-1 particles were taken up by iDCs to a high extent. Approximately 80% of 
immature cells successfully integrated bacterial MNPs. Due to their size and large magnetic 
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core structures, an iron amount of 50-65 pg/cell accumulated in positively selected iDCs 
(Figure 3.28B). 
TEM images as shown in Figure 3.28C support these results. MSR-1 particles consist of large 
iron cores linked by structural proteins, leading to their chain-like appearance
[213]
. According 
to high magnification TEM images, magnetic cores possess a diameter of 30-45 nm, which is 
extremely large compared to synthetic core sizes of other MNPs employed (refer to Table 
3.2). TEM images revealed that cells indeed completely internalized magnetosomes into 
intracellular compartments. As shown in Figure 3.28C (left image), endosomal compartments 
harboring MSR-1 clusters are confined to the cytosol. No magnetosomes were detected within 
nuclear regions or adhered to the outer cell membrane. Dendrites extending from the cell 
membrane could be observed, pointing towards an activated phenotype of labeled cells. 
In summary, bacterial magnetosomes were taken up to a high extent into iDCs. As visualized 
by TEM studies, organelles retained their chain-like structure inside endosomal compartments 
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after particle uptake. Furthermore, iDC membrane extrusions were clearly apparent, possibly 
providing evidence of an activated cellular phenotype. 
 
3.3.2.2 Phenotypic iDC Cytometry Profiling of Bacterial Magnetosomes 
Due to their bacterial origin and protein composure, bacterial magnetosomes were suspected 
to display an immunogenic nature when brought into proximity with in vitro generated 
phagocytic immune cells in previous experiments. Therefore, investigations as to the 
immunological impact of biogenic MNPs on immature iDCs using cytometry were conducted. 
In order to address surface marker profiles of bacterial magnetosomes, flow cytometric 
analyses were performed. iDCs were labeled for 24 h, magnetically sorted and stained for 
lineage- and DC-specific markers. 
Figure 3.29A+B display experimental settings used to analyze GM-CSF derived iDC 
populations. Live cell and doublet exclusion gating were selected prior to antibody gating 
strategies to exclude cell debris, dying cells or electronic measuring errors. Pre-gating on the 
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DC commitment marker CD11c
+
 ensured that only inflammatory dendritic cells were 
analyzed in subsequent cytometry experiments, excluding CD11c
-
 macrophage populations. 
As highlighted in Figure 3.29B, MHC II
high
, CD80
high
, and CD86
high
 cell fractions were used 
to evaluate iDC maturation state of MSR-1 magnetosomes in further experiments. 
Figure 3.30 depicts cytometry results acquired for MSR-1 particles after 24 h of labeling and 
subsequent magnetic separation. Gating strategy for GM-CSF derived iDCs followed 
procedures previously outlined in Figure 3.29A+B to exclude macrophage populations. 
However, in contrast to previous experimental results gained through FACS employing inert 
synthetic MNPs, MSR-1 particles induced the up-regulation of co-stimulatory surface 
molecules CD80 and CD86. MHC II, CD80 and CD86 surface expression proved to be 
significantly increased after 24 h of incubation time when compared to control levels. LPS is 
known to induce DC maturation and activation, and like MSR-1, approximately 80% of total 
iDC populations were found to be present within activated gates as outlined in Figure 3.29B. 
 
3.3.2.3 In Vitro Migration Assay using iDCs and MSR-1 Stimulation 
To further substantiate cytometric findings, in vitro migration assays in the context of 
MyD88
-/-
 knockout cells were performed. As previously noted, MyD88 represents a cardinal 
adapter protein crucial for TLR signaling cascades involved in cellular activation
[214]
. 
Receptor-mediated signaling in turn leads to NFκB-dependent activation of genes driving 
immunological consequences. Due to the bacterial nature of magnetosome organelles, 
involvement of TLR4 was suspected. 
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As shown in Figure 3.31, treatment of immature iDCs with magnetosomes resulted in a 
robust increase in the number of cells migrating towards increasing chemokine concentration. 
Baseline migratory behavior of unstimulated controls was attributed to the developmental 
heterogeneity arising within the in vitro cell culturing system. However, numbers of migrated 
cells remained within tolerance levels when compared to stimulated migratory iDCs. 
Treatment of cells with the positive control LPS resulted in comparable numbers of migratory 
iDCs when compared to MSR-1. Since LPS is known to signal via TLR4, it was not 
surprising that migratory behavior was significantly reduced in case of MyD88
-/- 
knockout 
cells. As displayed in Figure 3.31, the same holds true for MSR-1 stimulated cell populations, 
although to a lesser extent than in MyD88
-/-
 controls stimulated with LPS. In summary, MSR-
1 stimulated iDC populations showed profound migratory capacity after 24 h of biogenic 
MNP exposure that was significantly reduced in the case of MyD88 deficient knockout cells. 
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3.3.3 MSR-1 stimulated Flt3L-Generated DC Subsets 
3.3.3.1 FACS Profiling of MSR-1 Pulsed cDC Populations 
Figure 3.32 depicts numerical evaluation of CD80
high
CD86
high
 gates resulting as a 
consequence of the gating strategy employed in Figure 3.15. As previously reported 
employing GM-CSF derived iDCs, bacterial magnetosomes triggered significant up-
regulation of assessed surface marker levels in Wt Flt3L derived cDC populations. As shown 
in Figure 3.32A, PRR knockout models (TLR4
ko
, TLR9
ko
) as well as downstream adaptor 
molecule knockouts (MyD88
ko
, ASC
ko
) were employed to illustrate potential recognition 
mechanisms and resulting signaling dependencies. Cellular maturation due to LPS treatment 
resulted in the up-regulation of both CD80 and CD86 surface levels. Markedly, MSR-1 
stimulated Flt3L generated cDCs resulted in comparable surface molecule densities. Similar 
to LPS treatment, MSR-1 dependent up-regulation and activation of cells appeared to be 
TLR4 dependent. In the absence of functional TLR4, elevation of both CD80 and CD86 was 
significantly diminished. Due to the fact that TLR4 signals through MyD88, surface protein 
levels were also reduced in case of MyD88 knockout cells. TLR9 and ASC deficiency 
resulted in surface molecule levels similar to Wt conditions, illustrating the lack of 
involvement of these proteins in surface marker expression using MSR-1 magnetosomes. 
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In summary, MSR-1 treated cDC populations resulted in a robust increase of maturation 
dependent surface markers in cytometric measurements. A significant reduction of both TLR4 
and MyD88 deficient percentages was measured within respective gates of Flt3L derived 
cDCs. 
 
3.3.3.2 FACS Profiling of MSR-1 Pulsed pDC Populations 
Numerical data of MHC II
high
 and CD86
high
 gates are outlined in Figure 3.17. Even though 
pDCs did not yield activation levels of previously discussed cDCs after LPS stimulation, a 
significant increase in surface marker levels was noted. This increase in surface protein levels 
was also observed in pDC populations after MSR-1 stimulation (Figure 3.33). Values 
dropped down significantly in case of TLR4 knockout cells. LPS as well as MSR-1 
stimulation using TLR9 knockout cells resulted in a pronounced cellular activation 
comparable to Wt activation. This is in marked difference to unstimulated control pDCs that 
showed base-line presence of respective surface markers. 
In summary, both Wt and TLR9 knockout pDC were activated after magnetosome exposure. 
This activation was significantly reduced in case of TLR4 knockout cells similar to LPS 
control levels, pointing toward a signaling involvement of this respective pattern recognition 
receptor. 
 
3.3.3.3 Cytokine Release of Bulk Flt3L derived DC after Magnetosome Exposure 
The secretion of pro-inflammatory cytokines after cellular activation is an important feature 
of DCs resulting in the recruitment of additional cellular mediators driving the immune 
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response. To investigate the potential of bacterial MSR-1 magnetosomes to induce IL-6, IL-
12p40, and TNFα, supernatants of bulk DCs were collected after MNP exposure and ELISA 
measurements performed. 
As illustrated in Figure 3.34, labeling of bulk Flt3L generated cell cultures led to a 
pronounced secretion of pro-inflammatory cytokines in both WT and TLR9 knockout cells. 
Levels of LPS treated cells and bacterial magnetosomes resulted in comparable amounts of 
sequestered protein levels. However, secretion of cytokines was abolished in case of TLR4 
knockouts in both LPS and MSR-1 treated cells. Interestingly, sequestration of IL-12p40 was 
not altered when compared to Wt and TLR9 knockout cells. 
In summary, treatment of cDC and pDC bulk cultures led to a significant release of pro-
inflammatory cytokines after 24 h of incubation, undermining cytometric results previously 
discussed. 
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3.3.4 Bacterial Magnetosomes in the Context of MSR-1 
3.3.4.1 Phenotypic Analysis Employing Cytometry 
Next, the impact of bacterial magnetosomes on M-CSF derived macrophage populations was 
investigated. In normal physiological conditions, macrophages represent the first line of 
defense against invading pathogens and exogenously introduced MNPs. As shown in Figure 
3.35, cytometric data suggest cellular activation of MSR-1 pulsed macrophages due to the 
significant elevated levels of both CD86 and Mac-3. Gating strategy employed to yield 
macrophage populations is illustrated in Figure 3.20. Briefly, CD11b
+
CD11c
-
 gates were 
employed to exclude DCs arising throughout in vitro culturing. Surface expression of the 
macrophage marker F4/80 was employed to yield viable macrophages for subsequent data 
analyses. 
Mac-3 is already expressed to some extent in immature macrophage populations, however, 
elevated levels were recorded in both LPS and MSR-1 treated cells. Concomitantly, CD86 is 
further up-regulated after cellular activation in Wt cells. As shown in Figure 3.35, surface 
marker levels of TLR4 knockout macrophages are significantly reduced and display values 
similar to negative controls in both LPS and MSR-1 treated cells. 
 
3.3.4.2 Macrophage ELISA Data 
Macrophages are phagocytic cells of the innate immune system that sense potential harmful 
PAMPs and DAMPs within their immediate environment and react accordingly by recruiting 
other immune cells through the release of pro-inflammatory cytokines
[44]
. 
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To test whether M-CSF generated murine macrophages sense MNP formulations as 
potentially harmful, we performed ELISA measurements detecting released IL-6, IL-12p40, 
and TNFα in the context of TLR4 receptor knockout cells. 
As shown in Figure 3.36, biogenic MSR-1 led to a pronounced sequestration of IL-6, IL-
12p40, and TNFα in case of Wt macrophages. However, when employing TLR4 knockout 
cells, protein levels in supernatants were dramatically reduced, even though they remained 
elevated when compared to baseline levels in untreated controls. These experimental results 
are in agreement with data previously obtained, pointing at a high cellular activation potential 
of bacterial magnetosomes in a TLR4 dependent manner. 
 
3.3.5 Mixed Splenocytes in the Context of MSR-1 
Mixed splenocytes were harvested from explanted spleen and prepared to yield a homogenous 
cell population through mechanical disintegration as well as enzymatic action. MNP 
stimulation was carried out for a period of 72 h and cell numbers were assessed. These served 
as an indication of overall cell division events taking place as a result of MSR-1 exposure 
accumulating throughout the incubation time. 
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As depicted in Figure 3.37, approximately 0.5x10
6
 cells remained after 72 h of incubation in 
case of unstimulated control samples. On the other hand, LPS stimulated controls resulted in a 
3-fold increase of total splenocytes, whereas CpG treated populations did not alter cell 
numbers when compared to negative controls. 
MSR-1 proved to be able to induce cellular proliferation and division events under the 
experimental conditions. Total splenic cell populations after 72 h of incubation increased to 
approximately 1.5x10
6
 cells when compared to only 0.5x10
6
 in untreated control samples. 
 
3.3.6 Macrophages in the Context of Innate Immunity 
3.3.6.1 Magnetosomes and the Inflammasome Pathway 
The inflammasome is governed by a series of intracellular proteins and receptors responsible 
for the cleavage of caspase-1 that ultimately leads to the sequestration of functional IL-1ß. A 
series of proteins including the NOD-like and RLH receptors and NALP proteins are 
responsible for both (i) the recognition of antigens as well as (ii) mounting subsequent 
immunological consequences
[148]
. 
IL-1ß is a crucial inflammatory cytokine that that been shown to be particularly important in 
mounting an appropriate immune response against intracellular bacterial infections, especially 
in the context of endogenous danger signals
[148,215]
. In order for IL-1ß to be exported from the 
cytoplasm, two independent but synergistic steps are involved. First of all, the pro-enzyme 
caspase-1 has to be cleaved through the action of the ASC protein complex. This complex 
becomes activated by cytoplasmic nucleic acid sensors after severe tissue damage in the 
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context of invading pathogens
[216]
. Active caspase-1 is rendered to cleave intracellular pro-IL-
1ß that in turn gets released from the cell as a functional cytokine. Expression of pro-IL-1ß is 
interconnected with NFκB signaling that in turn leads to the sequestration of pro-
inflammatory cytokines itself. 
Adaptor proteins such as ASC are important in a hosts alertness and danger sensing capacities 
in the context of tissue damage and resulting pathogen invasion. Wounding is not only 
accompanied by tissue damage, but also serves as a primary entry point of exogenous 
pathogens such as bacteria and viruses. The immune system has evolved to cope with this 
particular situation by employing a series of intracellular proteins and receptors
[43]
. 
 
3.3.6.2 IL-1ß Sequestration and ASC Adaptor Protein Dependency 
As shown in Figure 3.38, induction and cleavage to form functional IL-1ß was observed for 
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bacterial magnetosomes MSR-1 after MNP stimulation. Other particles tested did not result in 
any up-regulation or induction of functional pro-inflammatory cytokines, and thus, are not 
likely to trigger the induction of the inflammasome pathway. For this reason, detection of 
released IL-1ß as a direct consequence of the activated inflammasome pathway was only 
investigated for bacterial magnetosomes. 
In order to stimulate TLR signaling and subsequent activation of cytokine release, LPS pre-
stimulation using a low-dose for 4 h was employed. However, neither LPS treatment alone 
nor LPS stimulation with a priming dose of LPS resulted in the release of functional IL-1ß. 
On the other hand, MSR-1 MNPs caused a significant amount of active IL-1ß to be 
sequestered into the culture medium even without priming macrophages with a low dose of 
LPS prior to particle stimulation overnight (Figure 3.38A+B). Furthermore, MSR-1 displayed 
induction of the inflammasome in an ASC dependent manner. ASC deficient cells were not 
able to recruit functional IL-1ß proteins, although levels of pro-inflammatory cytokines 
remained significantly elevated (Figure 3.38C+D). 
 
3.4 Concept of “Stealth” Particles and their Properties 
Usually DCs are well capable of ingesting virtually any foreign compound during their 
immature phenotypic state
[73]
. However, in modern medical applications such as diagnostic 
imaging of vasculature, this effect is undesirable because it reduces systemic half-life of MNP 
formulations and enhances clearance through the RES system. As a consequence, imaging 
vectors might not be able to reach and accumulate at the respective imaging target location or 
remain in circulation for the required imaging time frame. 
Therefore, Nitro-DOPA particles functionalized with PEG and biotin were employed that 
potentially evade uptake mechanisms to prolong their half-life in biological fluids. Particles 
that fulfill these criteria are often termed “stealth” particles and are being used for both 
imaging as well as drug delivery systems. 
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3.4.1 Inflammatory Dendritic Cells (iDCs) in the Context of “Stealth” MNPs 
3.4.1.1 Iron Oxide Uptake Properties and Quantification 
In order to test how coating materials affect residual uptake of “stealth” particles, two sets of 
surface coatings for each MNP formulation were employed. Both PEG and biotin are known 
for their biocompatibility as well as their potential to evade cellular uptake mechanisms. 
As displayed in Figure 3.39A, the percentage of total cells that successfully integrated MNPs 
was substantially reduced when compared to MNP formulations previously discussed. 
Strikingly, a correlation between the percentage of biotinylation as well as a relation to PEG 
molecular weight was observed. A higher degree of surface biotinylation on MNPs seemed to 
affect uptake rate in a negative manner. Similarly, a longer chain length of PEG resulted in a 
lower percentage of cellular uptake. Nitro-DOPA, representing the initial non-functionalized 
MNP formulation, was taken up the least. Only 8% of the total iDC population yielded 
successful MNP incorporation. 
Intracellular iron levels, however, proved to be within levels already shown for other MNP 
formulations. On average, 30-60 pg Fe/cell was taken up by immature iDCs (Figure 3.39B). 
The same trend of magnitude was observed in magnetic separation assays discussed in Figure 
3.42A. 
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Taken together, particles employed indeed provided “stealth” characteristics. Since immature 
iDC populations represent one of the most phagocytically active cell type, average quantity of 
uptake proved to be significantly decreased when compared to other MNP formulations 
employed in this study. Especially Biotin-MNPs conjugated with 10% surface structures 
evaded cellular uptake mechanisms, with less than 8% of cells being able to incorporate 
respective MNPs. 
 
3.4.1.2 Phenotypic Cytometry Analysis using iDCs 
In order to address surface marker profiles of synthesized “stealth” particles, flow cytometric 
analyses were performed. iDCs were labeled for 24 h, magnetically sorted and stained for 
lineage- and DC-specific markers. 
Figure 3.29 displays experimental settings used to analyze GM-CSF derived iDC populations. 
Live cell and doublet exclusion gating were selected prior to antibody gating strategies to 
exclude cell debris, dying cells or electronic measuring errors. Pre-gating on the DC 
commitment marker CD11c
+
 ensured that only conventional dendritic cells were analyzed in 
subsequent cytometric experiments, excluding CD11c
-
 macrophage populations. As 
exemplified in Figure 3.29B, MHC II
high
, CD80
high
 and CD86
high
 cell fractions were used to 
evaluate iDC maturation potential of “stealth” MNPs. 
Both PEGylated and biotinylated “stealth” particles proved to be biologically inert and 
displayed surface marker expression similar to those of untreated controls (Figure 3.40). 
Neither CD80/CD86 nor MHC II surface expression levels appeared to be elevated when 
compared to LPS positive controls. 24 h of labeling using LPS was employed to provide 
surface expression profiling of activated iDCs, as outlined in Figure 3.40. 
In summary, modification of non-functionalized Nitro-DOPA MNPs using PEG and Biotin 
moieties did not influence particle immunogenicity. All formulations employed proved to be 
biologically inert independent of their level of modification and surface decoration 
characteristics. 
 
 
 
R e s u l t s | 93 
 
 
3.4.2 “Stealth” MNP in the Context of Flt3L-Generated DCs 
3.4.2.1 Phenotypic Surface Marker Analysis of Flt3L-Generated cDCs 
Figure 3.41 depicts numerical evaluation of CD80
high
CD86
high
 gates as shown in Figure 3.15. 
As previously seen in similar experiments, “stealth” particles did not trigger an immune 
response in Wt as well as TLR4
ko
, TLR9
ko
, MyD88
ko
, and ASC
ko
 cells. Levels of surface 
expression are subject to small variations but remained within normal fluctuation levels. 
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3.4.2.2 “Stealth” Particles in the Context of Flt3L Derived pDCs 
In addition to generating cDCs, driving bone marrow derived progenitor cells into 
differentiation using Flt3L generates pDCs. These cells induce vast amount of IFNs upon 
cellular maturation and are critically involved in fighting viral infections, especially in a 
TLR9 dependent manner. 
Figure 3.17 depicts the gating strategy of Flt3L generated pDCs. Cells were selected for 
further experimental procedures including CD11c
+
CD11b
-
PDCA-1
+
B220
+ 
fractions of total 
live cells as depicted in Figure 3.17B. Levels of surface staining for MHC II and CD86 were 
evaluated and used for data acquisition and subsequent evaluation. Unstimulated control 
levels for both MHC II and CD86 gates were undetectable within selected gates. However, 
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numerical values within selected gates increased to 24% and 16% after cellular activation 
using LPS, respectively (Figure 3.26B). 
Numerical data of MHC II
high
 and CD86
high
 gates are outlined in Figure 3.42. Even though 
pDCs did not yield activation levels of cDCs after LPS stimulation, a significant increase in 
surface marker levels was noted. Values dropped down significantly in case of TLR4 
knockout cells. LPS stimulation using TLR9 knockout cells resulted in a pronounced cellular 
activation comparable to Wt activation. All “stealth” MNP formulations employed, however, 
did not alter surface expression levels of neither CD86 nor MHC II beyond the control 
baseline. 
 
3.4.2.3 Cytokine Release of Bulk DCs in the Context of “Stealth” Particles 
To further investigate cytokine release of DCs into their surroundings, ELISA experiments 
were performed. Detection of pro-inflammatory cytokines IL-6, IL-12p40, and TNFα were 
used to undermine data gathered during cytometric experiments as well as providing evidence 
as to the type of cellular activation. 
In addition to displaying an activated phenotype in FACS scans, DCs highly sequestrated all 
examined cytokines into their immediate environment upon stimulation with LPS in a TLR4 
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dependent manner (Figure 3.43). However, all “stealth” MNP formulations employed did not 
result in an increased release of pro-inflammatory cytokines. Protein content did not exceed 
base-line levels recorded for untreated controls, and thus, further undermined the inertness of 
particle formulations employed. 
 
3.4.3 “Stealth” MNP Pulsed Macrophages 
3.4.3.1 FACS Profiling of “Stealth” MNP Pulsed Macrophages 
Cytometric surface profiling of CD86 and Mac-3 was performed after MNP stimulation of M-
CSF generated murine macrophages in both the context of Wt and TLR4 knockout cells. 
Figure 3.44 illustrates macrophage FACS profiles obtained after 24 h of incubation with 
respective “stealth” MNPs. The gating strategy employed is illustrated in Figure 3.20. 
LPS yielded a significant up-regulation of both CD86 and Mac-3 surface proteins when 
compared to control levels. However, elevated presence of the respective molecules dropped 
down significantly in case of TLR4 receptor knockout cells. Neither Mac-3 nor CD86 levels 
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appeared to be elevated after exposure of macrophages to PEG and biotin MNP formulations, 
again substantiating the inertness of particles in the context of murine macrophages. 
 
3.4.3.2 ELISA Cytokine Secretion of M-CSF Generated Murine Macrophages 
In order to test the biological response of differentiated macrophages to “stealth” particle 
exposure, cytokine measurements were performed. Levels of IL-6, IL-12p40 and TNFα 
sequestration were investigated after 24 h of MNP exposure to adherently growing immature 
cells. 
As illustrated in Figure 3.45, “stealth” MNPs display neglectable levels of protein release as 
do untreated control macrophages. LPS resulted in the release of all three tested cytokines in a 
TLR4 dependent manner. 
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3.4.4 Splenocyte Responses to “Stealth” MNPs 
In order to test the immunological impact on bulk splenocyte cultures, explanted organs were 
dissociated and single cell suspensions labeled with respective “stealth” MNPs for 72 h under 
the influence of CFSE dye. This allows a fluorescent tracking of successive cellular division 
events that provides information about the potential of MNPs to induce T cell proliferation 
within the explanted splenocyte population. 
As illustrated in Figure 3.46, only LPS treatment resulted in the decrease of CFSE signal. 
“Stealth” MNPs did not induce cell proliferation of explanted bulk splenocyte populations 
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(Figure 3.46B) and total cell numbers remained within untreated control levels (Figure 
3.46A). 
 
3.5 Influence of Serum Components on MNP-iDC Interactions 
Recently, it has been demonstrated that proteins present in biological fluids such as i.e. blood 
serum or cell culture additives impact on MNP properties
[155]
. Especially charged MNPs 
adhere to opposingly charged proteins and are immediately covered by a film of biomolecules 
that alter their designed chemical MNP properties. This additional adherent soft protein shell 
ultimately changes particle-cell interactions such as recognition, mechanisms of endocytosis 
and clearance that strongly depend upon the nature of this protein “soft-shell” formed in 
aqueous solutions. 
Therefore, investigations regarding uptake and resulting imaging properties of MNPs in either 
the presence or absence of serum proteins were performed. 
 
3.5.1 Serum-Dependent Uptake Kinetics of MNPs 
Time course experiments were carried out to investigate uptake kinetics of MNPs. Since the 
apparent differences in uptake seemed to be present shortly after MNP exposure to protein 
content, time intervals were chosen between 1 min and 6 h. After that time period, levels of 
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uptake appeared to normalize when comparing serum-free and serum-containing MNP-
labeling environments (data not shown). 
As illustrated in Figure 3.47, positively charged particles such as PEI-MNP were taken up to 
a significantly higher degree in the absence of serum proteins. Almost 80% of PEI-MNP 
particles were taken up into the cells within the first few minutes of exposure, after which the 
amount taken up only increased marginally (20%). In serum-containing culture conditions, 
however, only 50% of PEI-MNP was taken up into cells after 1 min. 
The impact seemed to be abolished when dealing with negatively charged particles such as 
PSS-MNP, which was gradually taken up by iDCs. No difference was observed when 
comparing serum-free with serum-containing culture conditions. Surprisingly, PEG-coated 
MNPs also displayed both time- and serum-dependent differences in uptake properties. On 
the other hand, bacterial MSR-1 MNP did not show a significant difference when altering 
soluble protein concentration in culture medium. However, bacterial MSR-1 MNP was 
gradually taken up, with the maximum amount reached after 6 h. No further uptake was 
recorded beyond this time. 
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3.5.2 Serum-Dependency of Intracellular Iron Concentration 
It has been known for a long time that exogenous pathogens or compounds are being 
opsonized through various mechanisms such as antibody or complement binding to facilitate 
uptake into cells
[23]
. However, charged surfaces interact with ions and proteins in solution that 
loosely bind to particles through adhesive forces
[217]
. This could potentially implicate a 
masking of cellular target structures on MNPs, or, facilitate initial binding to structures of the 
plasma membrane that enhance subsequent uptake. 
To investigate these parameters, analyses to test whether the presence of serum constituents 
has an influence on MNP uptake quantity, namely intracellular iron content within labeled 
cells, were performed. As depicted in Figure 3.48, almost all MNPs tested were taken up to a 
higher degree without serum proteins present. However, PSS-MNP, a negatively charged 
particle, was taken up to the same degree in both experimental conditions. On the other hand, 
nearly twice the amount of iron was incorporated in the case of the bacterial magnetosome 
MSR-1. 
 
3.5.3 Impact of Protein “Corona” on MR Imaging Properties 
It can be envisioned that particle opsonization or adhesive protein layers shielding reactive 
surface moieties of MNP shell structures ultimately change packaging properties inside target 
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cells. In turn, altered intracellular particle density or agglomeration patterns could potentially 
change molecular imaging characteristics of contrast agents being employed. 
To investigate the impact of serum components on MNP imaging properties using MRI, in 
vitro phantom experiments were performed on successfully labeled iDCs. As shown in 
Figure 3.49, no significant differences were observed in signal reduction patterns when 
comparing target cell populations labeled under either serum-free or serum-containing 
conditions. All particles displayed the same magnitude of relaxation rate and detection limits 
under the two given experimental labeling conditions. 
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However, the linear relationship between relaxation rate R2 and cell seeding density appeared 
to be improved when imaging cells labeled under serum-free conditions. In particular, MSR-1 
R2 data showed substantial loss of linearity under protein-rich environments, whereas 
linearity was retained in the absence of serum components. 
 
3.6 Concept of Functionalized Acryl-MNPs 
Functionalization of particle surface structures represents a valuable research tool to enhance 
or guide performance and induction potential of MNPs regarding a defined target cell 
population
[177]
. Molecular moieties such as CpG motifs can be implemented on particle 
surfaces to drive immune cells towards a specific immunological phenotype that could 
potentially enhance (i) a desired treatment outcome and (ii) MR imaging properties. 
Nitro-DOPA MNPs coupled to acrylated functional groups were investigated as to their 
potential to covalently bind functional groups to their outermost anchor moieties. In this 
study, the possibility to enhance immunological capacity of MNP formulations by chemically 
ligating CpG motifs to their terminal structures to stimulate immature DCs, in particular 
pDCs, was investigated. Especially pDCs are known for their potential to become activated 
and release vast amount of type 1 interferons upon viral encounters, and thus, enhancement of 
cellular activation while lowering amounts of CpG needed was investigated. 
 
3.6.1 FACS Data of pDCs and Bulk Supernatant ELISA 
To validate successful MNP coupling strategies for CpG motifs onto target acrylated MNPs, a 
series of experimental measures were conducted. CpGs represent DNA analogues of viral 
origin and are recognized via endosomal TLR9 molecules within DCs. TLR9 is known to 
signal exclusively through the adaptor protein MyD88, and thus, cells deficient of this protein 
were included as controls in these experiments. 
In order to provide evidence as to coupling efficiency, magnetic purification steps were 
performed to exclude unbound CpGs within coupled MNP solutions that potentially trigger 
DC maturation without being coupled to designated target structures. As outlined in Figure 
3.50A+B, target CpGs alone, acrylated control MNPs without CpG ligation (acMNP), 
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purified CpG-coupled MNPs (after 1
st
, 2
nd
 purification), and resulting acrylated CpG-MNPs 
(after 3
rd
 purification) were employed. 
Bulk Flt3L generated DCs were subjected to particle formulations acquired during CpG 
coupling steps and tested for their potential to induce cellular maturation events leading to the 
up-regulation of surface co-stimulatory molecules, namely CD80 and CD86 (outlined in 
Figure 3.50A). 
As shown in Figure 3.50B, positive controls using LPS showed significant up-regulation of 
both surface markers in Wt and TLR9
-/-
 cells. Stimulation with CpG motifs alone resulted in a 
pronounced increase in the abundance of CD80/86 surface proteins; however, this effect was 
abolished in knockout cells. Acrylated MNP alone without coupling of target moieties did not 
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result in surface marker up-regulation beyond untreated control levels, providing evidence as 
to the inertness of the base particle formulation. 
Purified CpG-coupled MNPs (after 1
st
, 2
nd
 purification) displayed activation of pDC Wt 
populations to some extent; however, the effect seemed to be diminishing with increasing 
numbers of purification steps. Unfortunately, the resulting acrylated CpG-MNPs (after 3
rd
 
purification) lost all capacity to induce cellular maturation of bulk DC cultures, in particular 
pDC populations. 
 
3.6.2 ELISA Cytokine Secretion of Flt3L-Generated Bulk DCs 
In order to validate findings acquired with cytometry, supernatants of CpG-coupled MNPs 
were collected and subjected to ELISA. As outlined in Figure 3.51, pro-inflammatory 
cytokine levels of IL-6, IL-12p40, and TNFα of Wt cells were measured. 
LPS controls induced a dramatic increase of sequestered pro-inflammatory cytokines 
compared to untreated control baseline levels. Stimulation with CpG motifs alone induced the 
release of IL-12p40 and to some extent IL-6, whereas no TNFα was detected. Protein levels 
within supernatants collected of non-ligated acrylated particles (acMNP) displayed no 
elevation of released cytokines and levels were identical to untreated control samples. 
However, purified CpG-MNPs (after 2
nd
 purification and final acCpG-MNP) showed elevated 
levels of both IL-6 and IL-12p40, although only to a minor extent when compared to positive 
controls such as LPS and CpG motifs. 
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In summary, both cytometric and ELISA measurements revealed that non-ligated acrylated 
particles (acMNP) possess no immunogenicity. However, after the ligation of CpG motifs to 
the outermost layers of the particle shell through covalent binding strategies, no significant 
TLR9 dependent maturation of DCs remained after particle purification measures. 
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4 Discussion 
In the present study, an investigation of different MNP formulations was performed to assess 
the interaction and uptake phenomena that ultimately shape molecular imaging characteristics. 
It has been well established that exogenous particles are internalized by cell types of different 
origins and developmental stages after systemic and ex vivo MNP application
[174,218,219,220]
. In 
combination with their inherent biocompatibility and chemical stability, this finding has been 
the basis for employing iron-oxide based MNPs in molecular imaging and drug delivery 
regimes using MRI
[23,29,221]
. However, systematic studies addressing surface decoration and 
subsequent cellular consequences are still lacking and underlying mechanisms are poorly 
understood. Shaping particle surface moieties to confer a specific immunological and imaging 
goal remains to be a research area of great interest for future diagnostic and therapeutic 
applications
[222,223]
.  
For this reason, an experimental platform was generated in this study that allowed the 
investigation of interaction, uptake and resulting imaging characteristics involving 
synthetically engineered and biogenic nanoparticles in the context of cellular targets. It can be 
envisioned that functionalized surface moieties of MNPs impact on initial particle 
recognition, thus dictating routes of endocytosis and thereby influencing subsequent 
intracellular processing. Furthermore, these parameters ultimately shape resulting MRI 
properties. To achieve this functionalization, a wide range of surface moieties on MNPs were 
generated.  
LbL technology provides the means to actively shape particle attributes such as charge, 
overall size, and shell chemistry by employing charged poly-electrolytes as coating 
substrates
[162,224,225,226]
.Using this versatile technological platform, particle properties can be 
engineered depending upon the experimental goal. Furthermore, LbL provides a means to 
engraft biologically active macromolecules into MNP shells for further 
functionalization
[227,228,229]
. Poly-electrolyte coating of MNPs can be conceived to endow 
particle surfaces with desired properties resulting in (i) enhanced or even targeted uptake into 
cells, thereby augmenting MRI performance and (ii) providing additional functionalities such 
as immune-regulatory activities
[230]
. 
PEG and biotin are particularly suitable contrast agents for MRI due to their inherent property 
of evading systemic clearance, and thus, prolong circulation times
[167,231]
. To test how coating 
density affects cellular interactions, MNPs functionalized with PEG and biotin moieties 
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provided additional MNP platforms to further investigate the impact on biological target 
populations. For this purpose, a novel Nitro-DOPA anchoring group was employed to 
covalently attach surface moieties onto existing molecular MNP structures
[169]
. In addition, an 
attempt was pursued to further functionalize covalently modified acrylated MNPs with 
immunologically competent CpG antigenic structures that are known to confer TLR9 
dependent immunological consequences, especially in pDCs. 
Bacterial magnetosomes represent a class of biogenic nanoparticles that open the perspective 
to further amplify functionalization strategies through employing genetic engineering. Using 
this tactic, Scheffel et al. were recently able to fuse eGFP to the mamJ gene product of M. 
gryphiswaldense, thereby creating bimodal magnetosome imaging probes
[232]
. 
 
4.1 Chemical Stability and Biocompatibility of MNP Formulations 
Design criteria of MNPs employed in biomedical applications include both the acquisition of 
particle (i) stability as well as (ii) biocompatibility. Particle stability is conferred by layer(s) of 
substrates around the magnetic core of iron oxide particles
[233]
. Surface moieties usually grant 
particle monodispersity through charged molecules that drive MNP repulsion, thus leading to 
a homogenous distribution within solvents that inhibit undesirable agglomeration effects
[234]
. 
Furthermore, complete shielding of iron core structures conveys particle stability. It has been 
shown that incomplete coating strategies lead to premature particle degradation and severely 
decreased half-lives. Naked core particles tend to be highly chemically active and are prone to 
oxidation, leading to loss of magnetic properties and dispersibility
[235]
. 
Therefore, particles synthesized for the purpose of this study were analyzed using Zeta Sizing 
and Dynamic Light Scattering (DLS) technologies. As has been shown in several independent 
studies, these two techniques are successfully employed to verify particle properties such as 
overall hydrodynamic size and surface potential (Table 3.2)
[188,189]
. All MNPs tested resulted 
in a narrow size range and surface charge potential proving their stability and monodispersity. 
The only exception was Chit and Dex-MNP, whose parameters could not be determined 
successfully. This finding can be attributed to incomplete surface functionalization during 
synthesis procedures, thereby compromising particle stability and integrity. Due to the fact 
that multiple species ranging in size and surface potential were recorded, particle 
agglomeration most likely occurred in aqueous solution. However, due to the approved 
biocompatibility of both dextran and chitosan poly-saccharides, particles were included in this 
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study. Skebo et al. have shown that indeed incomplete surface modification leads to 
compromised integrity of MNP formulations
[236]
. On the other hand, however, all other poly-
electrolyte, lipid-shell and covalently functionalized MNPs employed herein proved to be 
chemically stable by presenting discrete sizes and surface potentials. 
However, even though biocompatibility of nano-scaled objects has been a focus of extensive 
research recently
[218,237]
, there is a need to constantly monitor and ensure the lack of 
potentially arising adverse effects on exposed biological systems, particularly in medical 
imaging regimes. Especially biomaterials used in medical implants and the growing number 
of nano-scaled particles employed in both medicine and industry pose a potential threat to 
biological systems
[154]
. 
In general, cellular cytotoxicity of MNPs in both experimental and clinical environments can 
be separated into two broad categories: Uptake-independent and uptake-dependent 
mechanisms. According to Soehnen et al., uptake-independent cytotoxic effects are exerted 
whenever large quantities of nanoparticle solutions are present without any cellular uptake 
mechanisms being involved
[196]
. Particle degradation products, excessive amount of MNPs 
within the cell’s immediate environment, and nutrient displacement potentially lead to 
adverse cellular viability effects
[238]
. Uptake-dependent cytotoxic effects on the other hand 
can be linked directly to MNP formulations being taken up by target cells. They arise as a 
consequence of reactive oxygen species (ROS) formation, the destruction of cellular 
compartments by chemical or mechanical forces, as well as ultimately leading to the induction 
of apoptosis
[154,239]
. 
In order to test these parameters on target cells, biocompatibility screenings were performed 
including both colorimetric MTT-based experimental procedures as well as 7-AAD 
fluorimetric cytometry approaches. While MTT results provided information about the 
resulting adverse effects on bulk populations including both uptake-dependent and uptake-
independent effects, 7-AAD data only considered successfully labeled target cells after 
magnetic separation procedures. However, with all cell types investigated, no significant 
adverse effects on cell populations were observed even when increasing iron oxide labeling 
concentrations by a factor of 20. It is worthwhile noting that both Chit and Dex-MNP resulted 
in elevated rates of cell death in HSCs when compared to terminally differentiated DCs 
(Figures 3.1+3.7). This finding can most likely be attributed to the endocytic capabilities of 
DCs being present as an integral biological asset of professional antigen scavenging cells
[116]
. 
On the other hand, HSC and their immediate downstream progenitors are not exposed to 
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exogenous antigens within their primary localization, and therefore, do not require endocytic 
properties. They are confined and shielded within their biological “niche”, whereas DCs 
reside in environments potentially encountering danger signals. As previously discussed, 
however, cytotoxicity observed with the cells types employed and particle formulations used 
is in agreement with previous studies employing similar MNPs and cell types. Under 
comparable experimental conditions, Soenen et al. have shown that iron oxide MNPs are 
usually well tolerated by progenitor cells up to a concentration of several mg/ml of iron 
content
[240]
. Terminally differentiated cells such as DCs and macrophages are capable of 
tolerating an even higher amount of iron oxide based nanoparticles. 
 
4.2 Uptake Properties and Intracellular Iron Deposition 
Uptake properties of MNPs into a given target cell population not only provide information 
about the efficiency of designed particle surface moieties, but in addition insights into 
molecular imaging characteristics
[241]
. Labeled cells are endowed with magnetic properties 
allowing a separation of fractions according to their MNP engulfment status. This separation 
technique was employed to allow both a quantitative as well as a qualitative assessment of the 
efficiency of MNPs taken up by target immune cells of various developmental and lineage 
origins. 
In this study, undifferentiated HSCs labeled with magnetic nanoparticles did not show a 
prominent uptake that can be attributed to their developmental stage and biological function. 
Previous studies using stem and progenitor cells showed similar results regarding labeling 
efficiencies employing iron oxide based nanoparticles
[33,242]
. Interestingly, we herein report an 
elevated uptake (2-fold) of bacterial magnetosomes into Flt3
+
 hematopoietic stem cells when 
compared to synthetic LbL poly-electrolyte and lipid-shell MNPs. This observation can be 
linked to the expression repertoire of PAMP recognition receptors on these stem cells and 
their immediate progenitors allowing them to respond to potential environmental threats
[243]
. 
However, due to the need for HSC labeling options in cell-based biomedical applications, 
especially charged poly-electrolyte MNPs such as PDAD-MNP and PEI-MNP proved to be 
taken up by a fairly large amount of target cells (Figure 3.2A). As shown by Weissleder et al. 
and others, this is due to the positively charged surface properties of these two contrast agents 
that allows electrostatic adherence to the negatively charged membrane structures of cells, and 
thus, facilitates endocytic uptake
[244,245]
. In contrast to professional phagocytes, intracellular 
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amount of iron oxide MNPs remained low but in agreement with labeling studies performed 
using different progenitor cell types (Figure 3.2B)
[202]
. 
Due to their biological function as professional phagocytic cells, immature DCs are capable of 
ingesting large amounts of MNPs. Charged poly-electrolytes and lipid-shell MNPs were taken 
up by the majority of cells, with more than 70% of exposed target populations being labeled 
after 24 h (Figure 3.8A). Again, electrostatic attractive and repulsive forces lead to the 
formation of so-called “protein corona” effects, opsonizing particle surface moieties and 
increasing subsequent MNP uptake
[155,159]
.  
Successful labeling of target cell populations such as i.e. DCs with contrast agents prior to 
implantation provides a means to non-invasively monitor cell fate using MRI. Therefore, 
efficient uptake of contrast agents by DCs allows detection of cell deposition and migration as 
previously reported by us and other groups
[171,246,247,248]
. 
Protein adsorbance and opsonization effects represent another area of intense research. In 
medical applications, chemical changes in the nature of a particular contrast agent or drug 
delivery system pose a great threat to the functionality of the delivered probe
[155]
. Therefore, 
scientists are eager to optimize coating strategies to minimize opsonization effects potentially 
resulting in enhanced clearance mechanisms through the immune and RES system as well as 
increasing therapeutic potential and overall stability of MNP formulations employed
[249]
. 
Covalently linked “stealth” particles employed in this study displayed significantly reduced 
uptake properties when compared to poly-electrolyte and lipid-shell MNPs (Figure 3.39). 
PEG and Biotin are well known to exert these characteristics and therefore represent suitable 
coating materials for certain biomedical imaging applications that convey increased 
circulation half-life
[249,250]
. Particle formulations coated with PEG and biotin were not taken 
up by cells to a high degree. Interestingly, cellular uptake was further diminished when 
increasing amount of MNP surface functionalization as shown employing covalently-linked 
biotinylated and PEGylated MNPs. Endowing particle formulations with similar “stealth” 
effects represents an area of intense research to further optimize imaging potential of 
nanoscaled vectors
[251]
. 
Especially charged particle surfaces are prone to be electrostatically covered by opposingly 
charged proteins leading to the formation of a secondary soft shell of various molecules in 
solution
[159,252]
. Ultimately, MNP interaction processes and subsequent uptake mechanisms 
are subject to change depending on the nature and magnitude of this particle sheathing. 
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As shown in this study, in particular positively charged MNP uptake characteristics are 
changed in that regard. During time-course experiments, PEI-MNP displayed significant 
alteration of uptake depending on the presence or absence of serum proteins. Maximum 
cellular uptake was reached after very short incubation times (below 30 min), after which no 
further increase was detected (Figure 3.47). However, even though uptake was dramatically 
increased when stimulating target cells with MNP in the absence of serum proteins, overall 
uptake kinetics remained unaltered for both experimental conditions. This finding provides 
evidence that particle uptake is enhanced due to charge-dependent adhesive forces exerted by 
the positively charged outer-most MNP layers. In several independent studies, it was shown 
that reactive serum components such as albumin and immunoglobulins have a high binding 
affinity to exogenously introduced matter such as MNPs
[159,253]
. Keeping these experimental 
outcomes in mind, it can be envisioned that opsonizing effects occurring in biological fluids 
change distinct parameters vital for successful imaging or even drug delivery systems. Cho et 
al. argue that these changes in chemical behavior of medical probes being administered to 
patients for the course of imaging or treatment could potentially alter the course of the desired 
MNP behavior
[254]
. However, no significant differences in MRI properties were noted when 
comparing protein-rich labeling environments with protein-low cell culturing conditions in 
this study (Figure 3.49). 
Furthermore, the bacterial magnetosome MSR-1 was taken up to a fairly high extent by iDCs. 
On average, 75% of cells incorporated bacterial MNPs resulting in the highest uptake of 
particles in these studies (Figure 3.28). This finding can be attributed to the immunogenicity 
of magnetosomes, resulting in phagocytic burst and enhanced uptake into target DCs in the 
course of cellular activation. The immature “surveillance” phenotype of DCs confers 
enhanced endocytic activity to provide maximum antigen monitoring capabilities of 
peripheral DCs. In the event of foreign antigen encounter, endocytosis is temporarily 
enhanced to increase antigenic load within endosomal structures
[255]
. This finding has been 
attributed to DCs and explains the drastic increase in labeling efficiency when compared to 
undifferentiated HSCs. As assessed through iron assays after magnetic separation, 
intracellular iron content was drastically increased in iDCs when compared to labeled HSCs 
(Figure 3.8B). DCs represent professional APCs biologically designed to take up vast 
amounts of extracellular materials, and thus resulted in high uptake quantities of MNP 
formulations. 
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Histological stainings provided information about the localization of iron oxide residues 
within labeled cells. Prussian blue staining patterns were localized intracellularly in numerous 
vesicles confined to the cytosol. MNPs were not found at the cell surface or within the 
nucleus. These results were consistent throughout all cell types examined and all MNP 
formulations employed, suggesting a global endocytic uptake mechanism. This finding is in 
agreement with previous studies proving shuttling of MNPs to early and late endosomes for 
subsequent degradation and processing
[256]
. 
Furthermore, investigations of iDCs using TEM displayed a strong correlation between MNP 
surface decoration and electron stopping power that has been reported in previous studies by 
Schwarz et al.
[175]
. It can be envisioned that adhesive or repulsive forces are responsible for 
individual particle agglomeration effects that shape intracellular trafficking and endosomal 
compartmentalization. It also has been known that endosomal compartments are low in pH, 
possibly contributing to exocytosis, MNP destabilization and clustering effects after 
uptake
[257]
. 
 
4.3 MRI Contrast Agent Potential 
Recently, MRI has advanced to an indispensable imaging modality due to its capacity to yield 
excellent high-resolution images of target tissues within a detailed anatomical context. In 
particular, in vitro labeling of target cells with nano-scaled contrast agents prior to 
implantation provides a powerful tool for tracking and monitoring cellular migration using 
MRI
[258,259]
. The potential of iron oxide based MNP formulations to serve as T2 and T2* 
shortening contrast agent to be used in clinical diagnosis and/or drug delivery systems have to 
be evaluated in order to establish a correlation between surface MNP decoration, target cell 
type to be labeled, and MR imaging properties
[18,23,174]
. Therefore, an evaluation of the 
molecular imaging properties was performed by employing high-resolution T2 and T2* 3D 
echo scans as well as map scans. The range of detection limits provided insights into minimal 
MNP-labeled cell numbers still being able to generate a local field inhomogeneity that can be 
visualized as signal reduction pattern with significant contrast. Iron oxide based particles 
influence MRI contrast due to changes in the local magnetic field homogeneity (T2* 
relaxation time) that depends on the magnetic moment and/or the size of the single particle. 
Larger particles, as shown from studies using micron-sized iron oxide particles, yield larger 
magnetic susceptibility that results in higher R2 and R2* relaxation rates
[33,260]
. 
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All iron oxide based particles employed in this study provided good imaging characteristics, 
however, intracellular shuttling parameters of individual MNPs resulted in changes with 
regard to MRI potential. As shown in several independent studies, T2 and T2* contrast of 
paramagnetic contrast agents is a result of MNP accumulation that results in a proton 
environment change of surrounding hydrogen protons present in water molecules
[261,262]
. The 
accumulation density, overall quantity of cellular MNP uptake, and intracellular packaging 
therefore lead to the formation of altered, yet MNP-specific imaging characteristics. In this 
study, it was demonstrated that PDAD-MNP is particularly suitable to trace labeled target 
cells populations down to a minimum seeding density of 10
2 
cells/drillhole (Figures 
3.13+3.14). This observation is in marked contrast to Chit-MNP, which could only be 
visualized down to a DC concentration of 10
4
 cells. We attribute this finding to the 
intracellular fate of engulfed particle formulations.  
Using TEM studies, we showed that different MNP formulations resulted in variable 
intracellular agglomeration effects within endosomal vesicles after successful uptake into 
iDCs (Figure 3.10). This observation was further supported by quantifying electron densities 
of MNP clusters within sub-cellular compartments in high-resolution TEM images. PDAD-
MNP provided highest electron stopping power as inferred from deduced numerical greyscale 
values. Interestingly, this in turn translated into favorable imaging characteristics as 
previously described by Schwarz et al.
[175]
. 
Generally speaking, an increase in molecular imaging properties can be achieved through 
increasing labeling concentrations, and thus, intracellular iron load. However, elevated 
intracellular iron oxide accumulation potentially leads to adverse cellular effects as previously 
discussed. In a given clinical setting, viability and functionality of employed cellular vectors 
remains crucial for diagnostic and therapeutic imaging outcome. Optimizing contrast agent 
performance with regard to sensitivity and specificity therefore allows targeted molecular 
imaging without compromising biocompatibility. 
 
4.4 Immunological Consequences after Contrast Agent Exposure 
Magnetic nanoparticles coated with polymeric structures have been known to be biologically 
inert, however, recent studies also provide data pointing towards an immunogenic potential of 
MNPs
[223,263]
. In medical diagnostics, these biological alterations are undesirable i.e. in the 
case of systemic administration of contrast agents prior to MRI scans. Furthermore, systemic 
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administration of contrast agents cannot result in systemic immune reactions that could 
potentially be fatal for the patient being imaged. On the other hand, there is a growing number 
of medical research aiming at exploiting immunological consequences of targeted MNP 
delivery systems as part of therapeutic treatment regimes
[13,14,264]
. Since immune cells sense 
foreign exogenous matter prior to other tissues, it is feasible to target them as vectors to 
convey a desired immunological endpoint that is favorable for such medical 
applications
[172,265]
.  
In order to test the involvement of both adaptor proteins and TLR receptors on signaling after 
MNP exposure, MyD88, TLR4 and TLR9 knockout cells were employed. It has been 
previously shown that TLRs and their downstream effector and adaptor molecules are crucial 
in initiating appropriate molecular countermeasures responsible for engaging exogenous 
threats such as bacteria and viruses
[92,93]
. Extracellular matter and particles that are taken up 
by phagocytosis mediated by pattern recognition receptors lead to a prominent up-regulation 
of cytokine and chemokine related genes involved in further immune-modulatory 
actions
[44,81]
. 
Therefore, MNP formulations employed herein were tested for their potential to alter 
phenotypic surface marker composition of hematopoietic cell types as an indication of 
potential immunogenicity. In case of undifferentiated progenitor cells, none of the employed 
MNP formulations caused a change in surface marker make-up including lineage markers 
(Figure 3.4), verifying that synthetic contrast agents employed in this study do not induce 
altered or even adverse phenotypic effects, and biological consequences to HSC remain 
minimal in a wide range of experimental conditions. This finding can be attributed to the low 
amount to particles being taken up by target cells and the given experimental conditions. 
However, due to the growing interest in medical treatment and reconstitution therapies 
involving multipotent stem cells in combination with molecular imaging techniques, possible 
adverse effects on target populations need to be evaluated. 
In case of the different DC subsets being employed in this study, no up-regulation of co-
stimulatory molecules that would confer immunological activity nor increased MHC II levels 
were detected in case of lipid-shell, polymer-based, and covalently functionalized MNPs. 
Therefore, MNP formulations can be expected to be biologically inert. These data are in 
agreement with studies addressing similar questions
[175]
. To further support this notion, 
secreted levels of pro-inflammatory cytokines were determined. In agreement with previously 
acquired cytometric data, no elevated release of IL-6, IL12p40, and TNFα was recorded for 
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all synthetic MNPs, providing additional evidence as to the inertness of particle formulations. 
However, Demento et al. showed that synthetic polymer MNPs do indeed have the potential 
to activate immune cells
[266]
. 
Biogenic MNPs derived from bacteria, on the other hand, displayed a strong potential to 
induce the up-regulation of differentiated cell types tested such as various DC subsets and 
macrophages. Even though magnetosomes employed are purified bacterial organelles, 
structural proteins linking single domain iron oxide cores could be the reason for MNP-
dependent up-regulation of co-stimulatory molecules CD80 and CD86 as well as MHC II. 
Significantly elevated levels of pro-inflammatory cytokines and cell proliferation events 
employing explanted cultures of splenocytes proved that biogenic magnetosomes indeed lead 
to an up-regulation of immune functions within these target cells. To address the involvement 
of PRRs and subsequent downstream NFκB signaling, knockout experiments employing 
TLR4, TLR9, and downstream adaptor protein MyD88 deficient cells were performed. 
In the context of these studies, bacterial magnetosomes displayed pronounced cellular 
activation potential in a TLR4 dependent manner. Both the absence of TLR4 and its 
downstream signaling molecule MyD88 resulted in the abrogation of immunological 
responses seen in Wt cells, providing evidence as to their dependency. Poly-electrolyte, lipid-
shell, and covalently functionalized “stealth” MNPs, however, did not show a significant 
response within target immune cells. As previously discussed in similar studies, this is most 
likely due to generalized endocytic uptake mechanisms
[125,126]
. In marked contrast, MSR-1 
MNPs were most likely taken up through receptor-mediated endocytosis, leading to 
maturation effects as shown in this study. 
In order to examine a possible involvement of the inflammasome in the presence of MNP 
formulations, M-CSF generated macrophages were pre-stimulated with a low priming dose of 
the TLR4 antagonist LPS. Several studies have shown the involvement of the inflammasome 
pathway in combination with administered contrast agents, which is desirable in the case of 
i.e. vaccine therapies. Particles being used serve as adjuvants in addition to providing 
molecular imaging characteristics. However, only the bacterial magnetosome MSR-1 resulted 
in pronounced IL-1ß release. Both LPS pre-stimulated as well as stimulation of macrophages 
with MSR-1 alone lead to an ASC-dependent cleavage of pro-IL-1ß and subsequent detection 
in supernatants (Figure 3.31). No other tested MNP formulation resulted in a marked initiation 
of the inflammasome pathway (data not shown). It was shown in this study that MSR-1 
involves TLR signaling, namely TLR4. In the absence of this PRR receptor in knockout 
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models, the cellular response is significantly diminished similar to LPS controls (Figures 
3.35+3.36). 
Furthermore, functionalizing acrylated MNPs with CpG motifs did not lead to the desirable 
TLR9 dependent immunological responses in pDCs (Figure 3.50). Even though CpG coupling 
motifs alone resulted in a pronounced up-regulation of both CD80 and CD86, residual cellular 
activation remaining after several MNP purifications ceased to control baseline levels. This 
served as an indication of uncompleted ligand coupling given the experimental settings. 
 
4.5 Concluding Remarks 
Taken together, this study provides insights into uptake and intracellular packaging properties 
in the context of different iron oxide based nanoparticles involving murine immune cells. The 
LbL technology proved to be highly valuable in shaping MNP surface characteristics that 
conferred enhanced cellular uptake and MR imaging properties, in particular the positively 
charged poly-electrolytes PDAD and PEI. In addition, oleate-stabilized lipid-shell MNPs 
provided a solid platform combining both good cellular uptake characteristics and MR 
imaging properties. Herein, we provide evidence that endocytic compartmentalization after 
successful uptake of MNP formulations markedly shapes resulting MR imaging properties.  
Therefore, our data suggest a critical involvement of MNP surface structures with regard to (i) 
cellular uptake and (ii) intracellular fate of administered contrast agents. Furthermore, these 
criteria impact on resulting imaging properties employing MRI as shown in this work. 
Inherent clustering properties of MNP formulations dependent on both (i) the particle 
chemistry and (ii) biological interactions can be expected to shape imaging as well as 
cellular/immunological results. Through shaping immunological consequences, as was 
observed in case of MSR-1, a specific induction of cellular phenotypes can be achieved. This 
includes both innate immunological countermeasures including i.e. the inflammasome and T 
cell mediated adaptive immune consequences. As intended, synthetic MNPs employed herein 
proved to be biologically inert in all experimental settings. In combination with their MRI 
potential, especially positively charged LbL poly-electrolyte MNPs represent a promising 
labeling vector for hematopoietic cells of various developmental stages. 
However, these data point towards the numerous variables that have to be accounted for when 
designing molecular probes for a specific imaging goal. Biological processes, particularly 
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during in vivo cell tracking or treatment monitoring, fundamentally shape or even alter the 
designed chemical properties of imaging agents dramatically. Surpassing current MNP 
limitations during the development of the next generation of MR contrast agents will be the 
focus of coming interdisciplinary research efforts. 
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6 Appendix 
 
6.1 Abbreviations 
7-AAD 7-Amino-Actinomycin D 
APC Antigen-Presenting cell 
APC AlloPhycoCyanin 
ASC Apoptosis-associated Speck-like protein containing a CARD 
BCR B-Cell Receptor 
Bx Magnetic field 
CCL CC-chemokine Ligand 
CCR CC-chemokine Receptor 
CD Cluster of Differentiation 
cDC conventional Dendritic Cell 
CDP Common DC Precursor 
CFSE CarboxyFluoresceine diacetate Succinimidyl Ester 
Chit Chitosan 
CLR C-type Lectin Receptor 
CME Clathrin-Mediated Endocytosis 
CNR Contrast to Noise Ratio 
CT Computed Tomography 
DAMP Danger-Associated Molecular Pattern 
DC Dendritic Cell 
dd double distilled 
Dex Dextran 
Dh Hydrodynamic diameter 
DMEM Dulbecco’s Modified Eagle Medium (culturing medium) 
DNA Deoxy-Ribonucleic Acid 
DTPA Di-ethylene-Tri-amine-Pent-Acetate 
ELISA Enzyme-Linked Immunosorbent Assay 
ER Endoplasmatic Reticulum 
EtOH Ethanol 
FACS Fluorescence Activated Cell Sorting 
Fc Fragment crystallizable 
FCS Fetal Calf Serum 
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Fe Iron 
Fe3O4 Magnetite 
FI Fluorescence Intensity 
FITC Fluorescein-Iso-Thio-Cyanate 
Flt3 FMS-Like Tyrosine kinase 3 
Gd Gadolinium 
GM-CSF Granulocyte Macrophage Colony-Stimulating Factor 
h Plank’s constant 
HSC Hematopoietic Stem Cell 
I Nuclear spin angular momentum 
iDC inflammatory Dendritic Cell 
IFN Interferon 
Ig Immunoglobulin 
IGF Insulin-like Growth Factor 
IL InterLeukin 
iNOS inducible Nitric Oxide Synthase 
k Boltzmann constant 
ko
 Knockout 
LbL Layer-by-Layer 
LC Langerhans Cell 
LP Lymphoid Precursor 
LPS Lipo-Poly-Saccharide 
M Net magnetization vector 
MBL Mannose-Binding Lectin 
M-CSF Macrophage Colony-Stimulating Factor 
MDP Monocyte, macrophage and DC Precursor 
MHC Major Histocompatibility Complex 
MION Monocrystalline Iron Oxide Nanoparticles 
MNP Magnetic NanoParticle 
MP Myeloid Precursor 
MR Mannose Receptor 
MRI Magnetic Resonance Imaging 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (dye) 
MyD88 Myeloid Differentiation primary response 88 
NALP NACHT, LRR and PYD domains-containing protein 
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NFκB nuclear factor kappa B 
NK cell Natural Killer cell 
NLR NOD-Like Receptor 
NO Nitric Oxide 
OLS Oleate-Stabilized Shell 
PAMP Pathogen-Associated Molecular Pattern 
PBS Phosphate Buffered Saline 
PDAD Poly-DiAllyl-Dimethyl ammonium chloride 
pDC plasmacytoid Dendritic Cell 
PE PhycoErythrin 
PEG Poly-Ethylene-Glycol 
PEI Poly-Ethylene-Imine 
PET Positron Emission Tomography 
PRR Pattern Recognition Receptor 
PSS Poly-Styrene-Sulfonate 
R Relaxivity 
RES Reticulo-Endothelial System 
RIG Retinoic acid-Inducible Gene 
RLH receptor RIG-I-Like RNA Helicase receptor 
RLR RIG-I-Like Receptor 
ROI Region Of Interest 
ROS Reactive Oxygen Species 
RPMI Roswell Park Memorial Institute (culturing medium) 
RT Room Temperature 
SCF Stem Cell Factor 
SDF Stromal cell-derived factor 
SPECT Single Photon Emission Computed Tomography 
SPIO Small Particles of Iron Oxide 
SR Scavenger Receptor 
T Tesla 
T1 Spin-lattice relaxation 
T2 Spin-spin relaxation 
TCR T-Cell Receptor 
TE Echo Time 
TEM Transmission Electron Microscopy 
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TIR Toll/Interleukin-1 Receptor 
TLR Toll-Like Receptor 
TNF Tumor Necrosis Factor 
TR Relaxation Time 
TRIF TIR-domain-containing adapter-Inducing IFN-β 
USPIO Ultra-Small Particles of Iron Oxide 
v/v Volume/volume 
VDJ Variable, Diversity, Joining 
Wt Wildtype 
γFe2O3 Maghemite 
ζ Zeta potential 
ω Larmor frequency 
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